Update of P2X receptor properties and their pharmacology: IUPHAR Review 30

Peter Illes1,2 Christa E. Müller3 Kenneth A. Jacobson4 Thomas Grutter5 Annette Nicke6 Samuel J. Fountain7 Charles Kennedy8 Günther Schmalzing9 Michael F. Jarvis10 Stanko S. Stojilkovic11 Brian F. King12 Francesco Di Virgilio13

1Rudolf Boehm Institute for Pharmacology and Toxicology, University of Leipzig, Leipzig, Germany
2International Collaborative Centre on Big Science Plan for Purinergic Signalling, Chengdu University of Traditional Chinese Medicine, Chengdu, China
3PharmaCenter Bonn, Pharmaceutical Institute, Pharmaceutical & Medicinal Chemistry, University of Bonn, Bonn, Germany
4Molecular Recognition Section, Laboratory of Bioorganic Chemistry, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, MD, USA
5University of Strasbourg, Centre National de la Recherche Scientifique, CAMB UMR 7199, Strasbourg, France
6Walther Straub Institute for Pharmacology and Toxicology, Ludwig-Maximilians-Universität München, Munich, Germany
7Faculty of Science, University of East Anglia, Norwich, UK
8Strathclyde Institute of Pharmacy and Biomedical Sciences, University of Strathclyde, Glasgow, UK
9Institute of Clinical Pharmacology, RWTH Aachen University, Aachen, Germany
10Global Medical Affairs, Abbvie, Inc., North Chicago, IL, USA
11Section on Cellular Signaling, The Eunice Kennedy Shriver National Institute of Child Health and Human Development, National Institutes of Health, Bethesda, MD, USA
12Department of Neuroscience, Physiology and Pharmacology, University College London, London, UK
13Department of Medical Sciences, Section of Experimental Medicine, University of Ferrara, Ferrara, Italy

Correspondence
Peter Illes, Rudolf Boehm Institute for Pharmacology and Toxicology, University of Leipzig, 04107 Leipzig, Germany.
Email: peter.illes@medizin.uni-leipzig.de

Funding information
European Union’s Horizon 2020. Grant/Award Number: 766124; Italian Association for Cancer Research, Grant/Award Number: 13025; Università degli Studi di Ferrara; Ministry of University and Research, Grant/Award Number: BYTNWC; Associazione Italiana per la Ricerca sul Cancro, Grant/Award Numbers: IG 22883, IG 18581, IG 13025; Deutsche Forschungsgemeinschaft, Grant/Award Number: 335447717–SFB 1328; Horizon 2020 Framework Programme;

The known seven mammalian receptor subunits (P2X1–7) form cationic channels gated by ATP. Three subunits compose a receptor channel. Each subunit is a polypeptide consisting of two transmembrane regions (TM1 and TM2), intracellular N- and C-termini, and a bulky extracellular loop. Crystallization allowed the identification of the 3D structure and gating cycle of P2X receptors. The agonist-binding pocket is located at the intersection of two neighbouring subunits. In addition to the mammalian P2X receptors, their primitive ligand-gated counterparts with little structural similarity have also been cloned. Selective agonists for P2X receptor subtypes are not available, but medicinal chemistry supplied a range of subtype-selective antagonists, as well as positive and negative allosteric modulators. Knockout mice and selective antagonists helped to identify pathological functions due to defective P2X receptors, such as

Abbreviations: AD, Alzheimer's disease; BBB, blood–brain barrier; BzATP, dibenzoyl-ATP; DRG, dorsal root ganglion; h, human; KO, knockout; m, mouse; NANC, non-adrenergic, non-cholinergic; PAM, positive allosteric modulator; r, rat; SE, status epilepticus; SNP, single nucleotide polymorphism; TM, transmembrane; TNP-ATP, trinitrophenyl-ATP; α,β-meATP, α,β-methylene ATP.

This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.

© 2020 The Authors. British Journal of Pharmacology published by John Wiley & Sons Ltd on behalf of British Pharmacological Society

Br J Pharmacol. 2021;178:489–514. wileyonlinelibrary.com/journal/bph
1 | INTRODUCTION

ATP, originally assumed to be exclusively the universal energy currency of cells, was proposed by Burnstock (1972) in his classic review to be an extracellular, non-adrenergic, non-cholinergic (NANC) neurotransmitter in smooth muscle organs of the gastrointestinal tract (see Verkhratsky, Zimmermann, Abbracchio, Illés, & Di Virgilio, 2020, for a fuller description of the evidence). After the acceptance of “NANC neurotransmission,” and the broadening of this hypothesis to the “co-transmission” idea (co-storage and co-release of ATP with acetylcholine (ACh) or noradrenaline; Burnstock, 1976), purine and pyrimidine nucleotides were then recognized to be extracellular signalling molecules that co-ordinate the function of almost every cell in the animal organisms, including humans (Burnstock & Knight, 2004). Receptors that are stimulated by these nucleotides have been classified into two types (Burnstock & Kennedy, 1985), the ligand-gated cationic channels termed P2X receptors with seven mammalian subtypes: P2X1–7 (Khakh et al., 2001) and the G protein-coupled P2Y receptors with eight mammalian subtypes: P2Y1,2,4,6,11 (Khakh et al., 2001) and the G protein-coupled P2Y receptors with seven mammalian subtypes: P2X1–7 (Khakh et al., 2001) and the G protein-coupled P2Y receptors with eight mammalian subtypes: P2Y1,2,4,6,11 (Khakh et al., 2001).

For P2Y receptors, an excellent new IUPHAR review is available, describing in detail the pharmaceutical data available on this class of receptors (Jacobson et al., 2020). However, our knowledge on P2X receptor nomenclature and subunit properties was last summarized in an official IUPHAR review in 2001 (Khakh et al., 2001), with an interim, and non-official updating in 2009 (Jarvis & Khakh, 2009). Hence, the aim of this review is to present a critical update of the recent developments in the pharmacological data available on this class of P2X receptors (i.e., generation of knockout [KO] animal models).

2 | MEDICINAL CHEMISTRY OF P2X RECEPTOR LIGANDS

The mammalian P2X receptors form homotrimeric or heterotrimeric channels, each of which harbours three ATP-binding sites. Table 1 summarizes the molecular and general pharmacological properties (agonist and antagonist potencies) of the seven P2X receptor subtypes. For this purpose, we have updated a most helpful table from a review by Jarvis and Khakh (2009) by including more recently discovered receptor ligands and introducing some recent developments (i.e., generation of knockout [KO] animal models).

2.1 | P2X receptor agonists

Despite high conservation of the ATP-binding site in each P2X receptor subtype, there are marked differences in the potency of ATP (1) (Table 1). It is active in the low micromolar to submicromolar range at all subtypes, except for the P2X7 receptor, which requires ATP concentrations in the hundreds of micromolar range for activation. P2X receptor agonists structurally derived from ATP have been described (see Figure 1), but agonists with high selectivity for a single subtype are presently not available (Jacobson & Müller, 2016; Lamberti et al., 2015). 2-Methylthio-ATP (2) and ATPγS (3) display a profile similar to that of ATP, but both compounds are metabolically more stable. α,β-Methylene ATP (4) shows a preference for P2X1 and P2X3 receptors with somewhat lower P2X4 receptor potency and much lower P2X7 receptor potency, while β,γ-methylene ATP (5) is most potent at P2X1 receptors and has only negligible potency at the other subtypes. 2’ (3’)-O-(4-benzoylbenzoyl)ATP (BzATP, 6) is sometimes described as a selective agonist for P2X7 receptors, but in fact, it has the highest potency at P2X1 receptors followed by P2X3 receptors (for data, see Table 1). Nonetheless, because it is approximately 10 times more potent than ATP, it is frequently used for activation of P2X7 receptors to avoid high, cytotoxic concentrations of ATP. 2’,3’-Substitution with bulky residues, as in trinitrophenyl (TNP)-ATP (7) and the P2X3 receptor antagonists 8 and 9 (DT-0111), or dinucleotide formation, as in diinosine pentaphosphate (Ip5), 10, can abolish agonistic activity leading to P2X receptor antagonists.

2.2 | Allosteric modulation of P2X receptors by physiological ions, lipids, steroids, and ethanol

P2X receptor function can be allosterically modulated by ions (e.g., Mg²⁺, Ca²⁺, and Zn²⁺; Table 1), steroids, bile acids, and lipids, for example, phosphatidylinositol polyphosphates such as Pl(4,5)P₂ (Bernier et al., 2008). The PIPs bind to positively charged amino acids in the cytosolic C-terminal domain and inhibit P2X receptor-mediated currents. The P2X4 receptors, and to some extent the P2X2 receptors, are inhibited by high ethanol concentrations (~100 mM) (Ilyaskin, Sure, Nesterov, Haertels, & Korbmacher, 2019; Müller, 2015; Sivcev et al., 2019).
### Table 1
Properties of recombinant homomeric P2X receptors and their pharmacology

| Molecular properties | P2X1 | P2X2 | P2X3 | P2X4 | P2X5 | P2X6 | P2X7 |
|----------------------|------|------|------|------|------|------|------|
| Gene name            | P2RX1 P2RX2 P2RX3 P2RX4 P2RX5 P2RX6 P2RX7 |
| Human chromosome location | 17p13.3 | 12q24.33 | 11q12.1 | 12q24.32 | 17p13.3 | 22q11.21 | 12q24.31 |
| Protein length (amino acids) | 399 | 471 | 397 | 388 | 444 | 441 | 595 |
| C tail length (amino acids) | 41 | 113 | 56 | 29 | 82 | 87 | 240 |
| Membrane expression | Good | Good | Good | Good | Poor | Usually no expression | Good |
| Desensitization (complete in) | Fast (<1 s) | Slow (>20 s) | Fast (<1 s) | Slow (>20 s) | Slow (>20 s) | — | Slow (>20 s) |
| Activation-dependent endocytosis | Yes | No | — | Yes | — | — | — |

### Pharmacology

#### Agonists (EC₅₀ values [μM]), Ref. 1, Ref. 7

| Agonist | P2X1 | P2X2 | P2X3 | P2X4 | P2X5 | P2X6 | P2X7 |
|---------|------|------|------|------|------|------|------|
| ATP 1   | 0.56–0.70 | 2–8 | 0.5–1 | 1–10 | 0.44–10 | 12 | 100 (r) |
| 2-MeSATP 2 | 0.07–1 | 1 | 0.35 | 0.29; 4.5 (r); 1.35 (m) | 0.5–10 | 9 | 178; |
| ATP₃ 3 | 2.3 | 1.5 (r) | 0.7 | 2.3 (r); 0.5; 0.6 (r); 1.3 (r) | 160 to >300; 1.1 (r) | >100 | >300 |
| α₃β₁-MeATP 4 | 0.1–1 | >300 | 0.74; 1–2 (r); 0.81; >100 (r, m) | 160 to >300; 1.1 (r) | >100 | >300 |
| β₂γ-MeATP 5 | 2 | >300 | >300 (r) | >300 | 11.8 (r) | — | — |
| BzATP 6 | 0.002 | 0.75 | 0.08 | 0.5; >100 (r); 2.9 (m) | 6–40; >500; | 25 | 5; 10–52 (r) |

#### Antagonists (IC₅₀ values [μM])

| Antagonist | P2X1 | P2X2 | P2X3 | P2X4 | P2X5 | P2X6 | P2X7 |
|------------|------|------|------|------|------|------|------|
| Suramin, Ref. 1 | 1–2 | 10 | 3 | >300 | 2–3 | — | >300 |
| PPADS | 1 | 1 | 1 | >500 | 3 | >100 | 10–50 |
| RB-2 14b, Ref. 1 | 30 (r) | 0.4–0.5 | — | — | 18.3 (r) | — | — |
| Auranin carboxylic acid | 0.008 (r) | 21.7 (r) | 0.0729 (r) | 763 (r) | — | — | 118 (r) |

#### Nucleotide-derived antagonists

| Antagonist | P2X1 | P2X2 | P2X3 | P2X4 | P2X5 | P2X6 | P2X7 |
|------------|------|------|------|------|------|------|------|
| TNP-ATP 7, Ref. 1, Ref. 5 | 0.006 | 1–2 | 0.001 | 1.5–15 | 0.45 (r) | — | >30 |
| 2′,3′-O-Benzylidene-ATP 8 | 0.002 | 5.5 | 0.08 | 0.49 | 40 | 25 | 52 |
| DT-01119 | — | — | 0.3 (P2X2/3) | — | — | — | — |
| IP5I 10, Ref. 1 | 0.003 | >300 | 2.8 | Potentiation | >30 (r) | — | — |

#### Non-nucleotide-derived antagonists

| Antagonist | P2X1 | P2X2 | P2X3 | P2X4 | P2X5 | P2X6 | P2X7 |
|------------|------|------|------|------|------|------|------|
| Non-nucleotide-derived antagonists | — | — | — | — | — | — | — |

P2X1 receptor antagonists
| P2X2 receptor antagonists | | | | | | | |
|--------------------------|--|--|--|--|--|--|--|
| P2X3 receptor antagonists | | | | | | | |
| Gefapixant (AF-219, MK-7264) 24, Ref. 4 | >10 | >100 | 0.1 | >100 | – | >100 | >100 |
| | >10 | 0.100–0.250 | 0.03 | >10 | >10 (r) | – | >10 |

P2X4 receptor antagonists

| | | | | | | | |
|--------------------------|--|--|--|--|--|--|--|
| P2X7 receptor antagonists | | | | | | | |
| | >100 | >100 | >100 | >100 | – | >100 | >100 |
| A-438079 34, Ref. 1 | >100 | >100 | >100 | >100 | – | >100 | 0.06–0.5 |
| A-804598 35 | >100 | >100 | >100 | >100 | – | >100 | 0.010 (h, r, m) |
| A-740003 36, Ref. 1 | >100 | >100 | >100 | >100 | – | >100 | 0.04–0.05; 0.02 (r) |
| AZ11645373 37 | >10 | >10 | >10 | >10 | – | – | 0.1 |

(Continues)
### Table 1 (Continued)

| NC-IUPHAR subunit nomenclature | P2X1 | P2X2 | P2X3 | P2X4 | P2X5 | P2X6 | P2X7 |
|--------------------------------|------|------|------|------|------|------|------|
| CE-224,535 38                  | >10  | -    | -    | -    | -    | -    | 0.002-0.013; inactive (rodent) |
| GSK14821 39                    | -    | -    | -    | -    | -    | -    | 0.003 |
| AZ0956 40                      | -    | -    | -    | -    | -    | -    | 0.012 |
| AZ106061 41                    | -    | -    | -    | -    | -    | -    | 0.0014 |
| JNJ479655 42                   | -    | -    | -    | -    | -    | -    | 0.005 |
| JNJ514754 43                   | -    | -    | -    | -    | -    | -    | 0.003 |
| [11C]JNJ-541737 44             | -    | -    | -    | -    | -    | -    | 0.0016 |
| [18F]JNJ-644137 45             | -    | -    | -    | -    | -    | -    | 0.015 |

Positive allosteric modulators (EC<sub>50</sub> values [μM])

| Ivermectin 11                  | -    | >30  | >30  | 0.25 | -    | -    | >30 (r, m), h |
| MRS2219 12                     | 5.9 (r) | >100 (r) | >100 (r) | >100 (r) | -    | -    | -    |
| PSB-10129 13                   | -    | 0.489| -    | Potentiation | Potentiation, block | -    | -    | -    |
| Cibacron Blue 14a             | IC<sub>50</sub> = 0.7 mM | -    | Potentiation | Potentiation, block | -    | -    | -    |
| Ginsenoside C-K 15             | -    | -    | -    | 8.5  | -    | -    | 1.1    |

Modulatory cations

| Zn<sup>2+</sup> | Decrease pKa 6.3 | Increase EC<sub>50</sub> = 7 μM | - | 8.5 |
| H<sup>+</sup>    | Increase pKa 7.3 | Decrease pKa 6.0 | Decrease pKa 6.8 | Decrease pKa 6.1 |

Physiology and pathophysiology

| Major cellular expression | Smooth muscle | Neurons | Pain-sensing neurons | Neurons, microglia | Skeletal muscle | Broad expression | Immune cells |
|---------------------------|---------------|---------|----------------------|-------------------|-----------------|------------------|-------------|
| Major role                | Neuroeffector transmission | Taste, hearing | Pain, bladder reflexes, taste | Vascular remodelling, neuropathic pain | Inflammatory bone loss | - | Inflammation, neurodegenerative illnesses |
| Model native cell type    | Vas deferens, myocytes | SCG, myenteric plexus neurons | Small DRG neurons | Macrophages | Skeletal myocytes | - | Monocytes, macrophages, microglia |
| KO available?             | Yes | Yes | Yes | Yes | Yes | Yes | Yes |

Note: The pharmacological values apply to homotrimeric receptors, unless noted. Bold numbers refer to chemical structures shown in Figures 1 and 2. Modified from Table 1 of Jarvis and Khakh (2009) with permission. Additional references are marked with numbers as follows: Ref. 1, Lambertucci et al. (2015); Ref. 2, Baqi et al. (2011); Ref. 3, Garceau and Chauret (2019); Ref. 4, Marucci et al. (2019); Ref. 5, Hernandez-Olmos et al. (2012); and Ref. 6, Werner et al. (2019).

Abbreviations: DRG, dorsal root ganglion; KO, knockout; NC-IUPHAR, International Union of Basic and Clinical Pharmacology Committee on Receptor Nomenclature and Drug Classification; SCG, superior cervical ganglion.

*Human (h) P2X receptor, unless noted (m, mouse; r, rat).*
**FIGURE 1**  Selected P2X receptor agonists, nucleotide-derived antagonists, and positive allosteric modulators

---

**P2X Receptor Agonists**

1. ATP
2. 2-Methylthio-ATP (2-MeS-ATP)
3. ATP$_7$S
4. α,β-Methylene-ATP
5. β,γ-Methylene-ATP
6. Benzoyl-ATP (BzATP) (mixture of 2'- and 3'-ester)

**P2X Receptor Antagonists - Nucleotides**

7. Trinitrophenyl-ATP (TNP-ATP)
8. 2',3'-O-Benzyldene-ATP
9. DT-0111
10. Ip5l

**Positive Allosteric Modulators of P2X Receptors**

11. Ivermectin
12. MRS2219
13. PSB-10129

R = ethyl: Ivermectin H2B1a (main component, > 90%)
R = methyl: Ivermectin H2B1b (minor component, < 10%)

14a. Cibachron Blue (o-sulfonate)
14b. Reactive Blue 2 (RB 2, mixture of m- and p-sulfonate)
15. Ginsenoside C-K
2.3 | Positive allosteric modulators of P2X receptors

Ivermectin (11, Figure 1), a CNS penetrant macrocyclic lactone used in veterinary and human medicine as an anti-parasitic agent, interacts with a variety of ion channels (Müller, 2015; Zemkova, Tvrdonova, Bhattacharya, & Jindrichova, 2014) and acts as a positive allosteric modulator (PAM) at P2X4 receptors, facilitating the opening and retarding the closing of the channel in the 100 nM to 3 μM range (Khakh, Proctor, Dunwiddie, Labarca, & Lester, 1999; Priel & Silberberg, 2004). At a similar concentration (3 μM), ivermectin is also active at the human (h), but not rat (r) and mouse (m) P2X7 receptors (Nörenberg et al., 2012). Structural modification of several antagonists has produced derivatives with positive modulatory activity. MRS2219 (12) selectively potentiates ATP-induced responses at recombinant rP2X1 receptors expressed in Xenopus laevis oocytes, with an EC50 of 5.9 μM (Jacobson et al., 1998). Among a series of P2X2 receptor antagonists with an anthraquinone core structure, several derivatives showed positive allosteric modulation. PSB-10129 (13) was one of the most potent PAMs of P2X2 receptors (EC50 = 489 nM), causing a threefold increase in the maximal ATP-elicited current (Baqi et al., 2011). The anthraquinone derivative Cibacron Blue (14a), which is one of the isomers present in Reactive Blue 2 (14b), is a PAM of hP2X3 and rP2X4 receptors (Baqi et al., 2011). It is non-selective and may also interact with other P2X receptor subtypes. Recently, ginsenosides, for example, 15, structurally related to steroids and representing the main constituents of the medicinal plant, ginseng (Panax ginseng), were found to act as P2X4 receptor PAMs (Dhuna et al., 2019). The development of PAMs may be a promising approach for drug development, since selectivity for orthosteric agonists will be difficult to achieve.

2.4 | Non-selective P2X receptor antagonists

Moderately potent, non-selective P2X receptor antagonists include suramin, Reactive Blue 2 (14b, Figure 2), PPADS, and iso-PPADS. They are of limited use and should be replaced by more potent and selective antagonists that are now available. The ATP derivative TNP-ATP (7) is very potent at P2X1 and P2X3 receptors (low nanomolar IC50 values), much less potent at P2X2 and P2X4 receptors, and virtually inactive at P2X7 receptors (Dal Ben et al., 2019). Ips3 (10) is most potent as a P2X1 receptor antagonist and also blocks P2X3 receptors, but not the heteromeric P2X2/3 receptors, while it potentiates P2X4 receptors (Lambertucci et al., 2015). Recently, aurintricarboxylic acid, a potent inhibitor of nucleases, was reported to strongly block P2X1 and P2X3 receptors in a non-competitive manner (Obrecht et al., 2019).

2.5 | P2X1 receptor antagonists

Only a few P2X1 receptor-selective antagonists have been developed (Figure 2). Salicylamide derivatives with high potency and selectivity were recently described (Tian et al., 2020), representing small, uncharged molecules, which act as negative allosteric modulators (NAMs). Some of them, for example, PSB-2014 (16b), only partly inhibited hP2X1 receptors. Suramin derivatives, for example, NF279 (17) and NF023 (18), appear to be competitive antagonists. MRS2159 (19), derived from PPADS, binds covalently to the orthosteric binding site of the receptor (Erhardt, Pillarissetti, & Toomey, 2003) but may also block P2X7 receptors (Donnelly-Roberts, Namovic, Han, & Jarvis, 2009).

2.6 | P2X2 receptor antagonists

Only a few selective P2X2 receptor antagonists have been developed (Figure 2). The anionic standard P2X receptor antagonists - PPADS, Reactive Blue 2 (14b), TNP-ATP (7), and suramin - are moderately potent, non-selective P2X2 receptor antagonists. The suramin derivative, NF770 (20), is more potent and selective for P2X2 than to the other P2X2 receptors, and evidence was presented for a competitive mechanism of action (Wolf et al., 2011). Potent and selective P2X2 receptor antagonists related to Reactive Blue 2 have been developed, such as PSB-10211 (21) and PSB-1011 (22) (Baqi et al., 2011).

2.7 | P2X3 receptor antagonists

Many potent, selective P2X3 receptor antagonists have been developed (Ford, 2012; Marucci et al., 2019; Müller, 2010) (Figure 2). One of the first was A-317491 (23), a tricarboxylate, which binds to the ATP-binding site, acting as a competitive antagonist (Jarvis et al., 2002). It displays low peroral and CNS bioavailability and high plasma–protein binding. 2’-3’-Benzylidine-ATP (8) and related ATP derivatives have submicromolar potency and some P2X3 receptor selectivity (Dal Ben et al., 2019). The 3’-benzamido-ATP derivative, DT-0111 (9), was developed as a water-soluble P2X2/3 receptor antagonist suitable for administration by inhalation (Pellegr, Xu, Zhuang, Undem, & Burnstock, 2019). It has an IC50 value of 0.3 μM, as well as high selectivity, and represents a drug candidate for chronic obstructive pulmonary disease, chronic cough and overactive urinary bladder (Pellegr, Xu, Zhuang, Undem, & Burnstock, 2019).

A series of allosteric antagonists were discovered in a high-throughput screening campaign centred on the drug trimethoprim (for reviews, see Müller, 2010, 2015). Gefapixant (24), named after Geoffrey Burnstock (“Gef” sounds the same as “Geoff”), has been advanced to clinical trials for chronic cough (Morice et al., 2019). Further potent and selective derivatives of this series include AF-353 (25) and AF-906 (26). AF-353 displays IC50 values of 6 nM (hP2X3 receptors), 13 nM (rP2X3 receptors), and 25 nM (hP2X2/3 receptors) and is selective versus P2X1, P2X2, P2X5, and P2X7 receptors (IC50 > 10 μM) as well as a range of other targets. It shows peroral bioavailability and is brain penetrant. AF-906 displayed superior pharmacokinetic properties and IC50 values of 2 nM (hP2X3 receptors) and 5 nM (hP2X2/3 receptors). The imidazopyridine derivative BLU-5937
P2X1 Receptor Antagonists

16a R = 5-Cl  PSB-2001
16b R = 4-Cl  PSB-2014
16c R = 3-Cl  PSB-2013

17 NF279
18 NF023
19 MRS2159

P2X2 Receptor Antagonists

20 NF770
21 PSB-10211
22 PSB-1011

P2X3 Receptor Antagonists

23 A-317491
24 Gefapixant (AF-219, MK-7254)
25 AF-353 (RO-4)
26 AF-906 (RO-51)
27 BLU-5937

P2X4 Receptor Antagonists

28 5-BDBD
29 NP-1815-PX
30 PSB-12054
31 PSB-12062
32 BX430
33 BAY-1797

P2X7 Receptor Antagonists

34 A-438079
35 A-804598
36 A-740003
37 AZ11645373

38 CE-224,535
39 GSK1482160
40 AZD9056
41 AZ10006120

42 JNJ47995567
43 JNJ-54175446
44 [1^3C]JNJ-54173717
45 [125I]JNJ-64413739

FIGURE 2  P2X receptor subtype-selective antagonists
was reported to be selective for the homomeric P2X3 receptors versus the heteromeric P2X2/3 receptors and therefore, in contrast to gefapixant, is expected not to affect taste sensing. The compound is being evaluated clinically for chronic cough and pruritus (Garceau & Chauret, 2019).

2.8 | P2X4 receptor antagonists

The benzodiazepine derivative 5-BDBD (28, Figure 2) is a moderately potent (IC$_{50} = 0.5$ μM), selective allosteric P2X4 receptor antagonist (Abdelrahman et al., 2017). It displays low water solubility and is therefore not easily handled. NP-1815-PX (29) is a related compound with increased water solubility (Matsumura et al., 2016). A possibly related compound, NC-2600 (structure not disclosed), entered clinical trials for neuropathic pain, but after a phase I study, no further development has been reported. The allosteric P2X4 receptor antagonist, N-(benzyloxy carbonyl)phenoxazine (PSB-12054, 30), exhibited an IC$_{50}$ of 0.2 μM at the hP2X4, but was less potent at rP2X4 (2.1 μM) and mP2X4 receptors (1.8 μM) (Hernandez-Olmos et al., 2012). A drawback is its high lipophilicity and moderate water solubility. A more water-soluble analogue is PSB-12062 (31), the N-(p-methylphenylsulfonyl)-substituted phenoxazine. It was similarly potent at hP2X4 (IC$_{50} = 1.4$ μM),

![Figure 3](https://example.com/figure3.png)

**FIGURE 3** Structures of selected P2X receptors. (a) Structure of the hP2X3 receptor bound to ATP (PDB ID: 5SVK) (Mansoor et al., 2016). The hP2X3 receptor is shown in blue cartoon representation, and ATP is shown as spheres (carbon is yellow, oxygen is red, nitrogen is blue, and phosphorus is orange). Horizontal grey bars indicate the approximate location of the membrane bilayer defining the extracellular (out) and intracellular (in) milieu. (b) Structure of zfP2X4 receptor bound to ATP (4DW1) (Hattori & Gouaux, 2012). The zfP2X4 receptor is shown in green cartoon representation, and ATP is shown as spheres. (c) Structure of the rP2X7 receptor bound to ATP (6U9W) (McCarthy, Yoshioka, & Mansoor, 2019). The rP2X7 receptor is shown in cyan cartoon representation, and ATP is shown as spheres. (d) Structure of the invertebrate AmP2X receptor bound to ATP (5F1C) (Kasuya et al., 2016). The AmP2X receptor is shown in orange cartoon representation, and ATP is shown as spheres. Note the structural similarity between vertebrate and invertebrate P2X receptors. For structures having undergone heavy truncations, membrane spanning helices are lacking in their intracellular sides. (e–g) Close-up views of ATP-binding sites from hP2X3 receptors (e), zfP2X4 receptors (f), and rP2X7 receptors (g). For comparison, views are taken from similar angles, and displayed residues are equivalent across P2X receptors, except for S275 and K193. For those not directly contributing to ATP binding (distance >3.5 Å), equivalent residues are not displayed (e.g., K64 in rP2X7 receptors). ATP is shown in stick representation (carbon is yellow, oxygen red, nitrogen blue, and phosphorus orange) with positions of α-, β-, and γ-phosphate. The oxygen atom from a glycerol molecule (GOL) is shown in sphere representation. Black dashed lines indicate hydrogen bonding (<3.5 Å), AmP2XR, Gulf Coast tick *Amblyomma maculatum* P2X receptor; hP2X3R, human P2X3 receptor; rP2X7R, rat P2X7 receptor; zfP2X4R, zebrafish P2X4 receptor
rP2X4 (0.9 μM), and mP2X4 receptors (1.8 μM) and showed selectivity versus P2X1, P2X3 and P2X7 receptors (Hernandez-Olmos et al., 2012). The urea derivative BX430 (32) was identified by compound library screening as an allosteric antagonist with an IC50 value of 0.5 μM at the hP2X4 receptor. It showed selectivity versus other P2X receptor subtypes but had no effect on mP2X4 and rP2X4 receptors (Ase, Honson, Zaghdane, Pfeifer, & Seguela, 2015). The sulfonamide BAY-1797 (33) was recently presented as a compound with an IC50 of 210 nM at the hP2X4 receptor and high selectivity (Werner et al., 2019). This antagonist shows high water solubility and no brain penetration. The potent and selective P2X4 receptor antagonist PSB-15417 (structure undisclosed), a brain-penetrant compound, showed high activity in animal models of neuropathic pain (Teixeira et al., 2019).

2.9 | P2X7 receptor antagonists

The P2X7 receptor has been the most extensively investigated subtype for drug development, and numerous potent and selective, mainly allosteric, antagonists have been reported (Gelin, Bhattacharya, & Letavic, 2020). The sulfonate dye Brilliant Blue G blocks P2X7 receptors and has been used in a number of studies due to its low cost. However, improved P2X7 receptor antagonists with suitable pharmacokinetic properties are available (Gelin, Bhattacharya, & Letavic, 2020; Rech, Bhattacharya, Letavic, & Savall, 2016) and should be used instead. As for many allosteric modulators, species differences have been observed for some P2X7 receptor antagonists. The very first clinical studies were performed with allosteric P2X7 receptor antagonists, such as AZD9056 (40) to treat rheumatoid arthritis, but their effectiveness for this indication was not convincing. Useful P2X7 receptor antagonists (34–45, Figure 2) belong to a range of chemical compound classes. Some, for example, 43, show high brain permeability. JNJ54175446 (43) has been clinically evaluated for the treatment of major depression and bipolar disorders. 11C and 18F tracers (44 and 45) for PET have been developed.

3 | GENERAL STRUCTURE OF P2X RECEPTORS

To date, 27 high-resolution P2X receptor structures have been solved, all within the last decade and all obtained from truncated subunits, except for rP2X7, for which the full-length structure has been solved. Supported by structural data obtained from vertebrate and invertebrate receptors, there is now strong evidence that P2X receptors share similar tertiary and quaternary architecture, further confirming the hypothesis that all P2X receptors belong to the same structural and evolutionary group (Figure 3a–d).

The structural analysis revealed a chalice-like, trimeric assembly of three subunit monomers, with the extracellular domain protruding 70 Å above the plasma membrane plane, and the transmembrane (TM) domain, which is composed of six TM α-helices (two from each subunit) forming the ionic pore, extending approximately 28 Å into the membrane. The intracellular domain protrudes less than the extracellular domain and contains the “cytoplasmic cap,” a highly intertwined region, rich in β-sheets, which is formed by domain swapping of the N- and C-termini of all three subunits. The intracellular region of the rP2X7 receptor contains two additional domains: the cysteine-rich C-cys anchor and the cytoplasmic ballast, both located at the C-terminal end (McCarthy, Yoshioka, & Mansoor, 2019) (Figure 3c).

3.1 | Agonist sites

Three ATP-binding sites are found in the extracellular domain within large, interfacial pockets located ~40 Å from the TM domain. ATP-bound structures reveal that the phosphates of ATP bind to several highly conserved, positively charged (e.g., Lys70, Lys72, Arg298, and Lys316 in zfP2X4R) and polar (Asn296) residues (Figure 3e–g). Structures further showed that ATP unexpectedly adopts an unusual U-shaped conformation, allowing the adenine base of ATP to be deeply buried in the binding pocket and recognized by polar (Lys70 and Thr189) and hydrophobic interactions (Leu191 and Ile232). The ribose ring of ATP is recognized by non-polar residues (Leu217), while the O1 and O2 atoms of the ring are rather solvent accessible. Structures of other bound agonists, such as 2-methylthio-ATP (Mansoor et al., 2016) and CTP (Kasuya, Fujiwara, et al., 2017), reveal similar binding modes and orientations, although subtle differences exist, in particular in the base recognition. Interestingly, the entrance to the binding pocket of the P2X7 receptor (~11-Å orifice) (McCarthy, Yoshioka, & Mansoor, 2019) is much narrower than that of other P2X receptors, for example, the P2X3 receptor (~17-Å orifice) (Mansoor et al., 2016). This may reduce drug accessibility to the binding pocket and so contribute to the three orders of magnitude lower potency of ATP at the P2X7 receptor compared with other P2X receptor subtypes. Nonetheless, these structural data strongly suggest that the molecular rules governing agonist recognition are highly conserved across P2X receptors and species.

3.2 | Antagonist sites

Molecular rules governing competitive antagonist binding seem less stringent than those of agonists. Structures of bound competitive antagonists, such as TNP-ATP or A-317491, reveal significant differences in both binding modes and orientations, when compared with agonist-bound structures. Although TNP-ATP and A-317491 occupy the orthosteric site, they bind more deeply in the binding cleft than ATP, adopting either a Y shape (Mansoor et al., 2016) or an extended conformation (Kasuya, Yamaura, et al., 2017). Compared with the high structural constrains imposed by agonist binding, conformational flexibility of bound competitive antagonists may explain why they do not produce channel opening.
3.3 | Allosteric sites

Structures with several bound non-competitive inhibitors also reveal molecular details of allosteric antagonism in P2X receptors (Coddou, Stojilkovic, & Huidobro-Toro, 2011; Habermacher, Dunning, Chataigneau, & Grutter, 2016), and at least two have been resolved at the level of atomic detail: One is located near the apex of the panda P2X7 receptor (Karawasa & Kawate, 2016) and the other one just beneath the orthosteric binding site in the hP2X3 receptor (Wang et al., 2018). Occupancy of these allosteric sites is thought to prevent mechanical motions involved in channel gating. Other allosteric sites are also present in P2X receptors, including sites in the TM that are regulated by phospholipids (Karawasa, Michalski, Mikhelzon, & Kawate, 2017), but their definitive locations have not yet been confirmed by high-resolution structural studies.

3.4 | Gating cycle

Of the 27 high-resolution structures, six have been solved in an apparent open channel conformation, bound to ATP, and three in a desensitized, closed channel state, bound to either ATP or 2-methylthio-ATP. Based on these structures, gating cycle models have been proposed for desensitizing (Mansoor et al., 2016) and non-desensitizing channels (McCarthy, Yoshioka, & Mansoor, 2019). Although these structures were all solved in detergents (i.e., in non-native phospholipid bilayers), they provide important clues on channel gating and desensitization mechanisms. Supported by experimental data (see references cited in Habermacher, Dunning, Chataigneau, & Grutter, 2016), it is thought that ATP binding induces a series of structural changes, from tightening of the binding pocket to the outward expansion of the six TM α-helices, leading to channel opening.

Interestingly, the helical pitch of the three innermost TM2 helices changes from an α- to a 3_10-helix during channel opening. Due to the presence of the cytoplasmic cap, this helical stretching is energetically compensated (Mansoor et al., 2016), which results in the stabilization of the open channel state. However, it appears that during desensitization, TM2 helices recoil as the cytoplasmic cap dis-assembles. Therefore, the structural stability of the cytoplasmic cap appears to tune the rate and extent of desensitization, whereby fast-desensitizing P2X receptors have a less stable cap, compared with slowly or non-desensitizing receptors, such as P2X7 receptors, which possess a more stable cap (McCarthy, Yoshioka, & Mansoor, 2019).

4 | P2X RECEPTOR MOUSE MODELS

The major phenotypes of P2X receptor KO mice are summarized below. For detailed information and references, see Figure 4, Kaczmarek-Hajek, Lörinczi, Hausmann, and Nicke (2012), Jimenez-Mateos, Smith, Nicke and Engel (2019), http://www.informatics.jax.org/, and http://www.findmice.org/. Changes caused by the deletion of individual P2X receptors will be discussed in detail in the specific P2X receptor sections.

Consistent with P2X1 receptor expression, P2x1tm1Chn mice show a smooth muscle (90% reduced male fertility and slight hypertension) and a prothrombotic phenotype. Despite abundant P2X2 receptor expression in neuronal and non-neuronal tissues, P2nx2tm1Chn mice present a mild phenotype, with impaired neurotransmission, for example, in pelvic afferent nerves, carotid sinus nerve, and sensory ganglia. A role for cochlear P2X2 receptors in noise adaption and hearing loss was found in P2nx2tm1Chn mice and in humans carrying a P2X2 receptor mutation. P2nx3tm1Chn and P2nx3tm1Lex are less sensitive to inflammatory pain, but not acute noxious thermal (hot plate) and mechanical stimuli. However, using different assays, thermal hyperresponsiveness was observed and compensatory effects were suggested. Like P2nx2tm1Chn mice, P2nx3tm1Lex mice showed bladder hyporeflexia and impaired peristalsis and additionally altered hippocampal synaptic plasticity. P2nx2/P2nx3tm1Lex mice have gustatory deficits and show developmental abnormalities and high lethality due to pneumonia, probably resulting from reduced ventilatory responses to hypoxia. Surviving mice appear normal. P2x4tm1Rasq and P2x4tm1Rasd mice confirmed the involvement of spinal microglial P2X4 receptors in chronic inflammatory and neuropathic pain. Investigation of P2x4tm1Ando mice also revealed a role of endothelial P2X4 receptors in vascular functions, resulting in high blood pressure (BP). In P2x4tm1Rasq mice, altered hippocampal synaptic plasticity and perceptual and socio-communciative deficits were described. A mouse model in which P2X4 receptor-mCherry expression in the plasma membrane can be conditionally increased (P2x4mCherryIN) revealed anxiolytic effects and learning deficits. Transgenic hP2X4 receptor-overexpressing mice exhibit increased myocyte contractility, while cardiac-specific P2X4 receptor KO mice (P2x4tm1Ngt) show more severe heart failure. P2x4tm1Dgen showed abnormal macrophage function. P2X5 receptors are widely distributed in murine tissues; osteoclasts from P2x5tm−/− mice were shown to have deficits in inflammasome activation and osteoclast maturation under inflammatory conditions (Kim et al., 2017). P2x5tm1Lex mice showed altered immune cell numbers and learning/exploratory behaviour. P2x6tm1Dgen mice showed a pain phenotype.

At least seven P2x7tm−/− mouse lines have been generated and show deficits in immune function, cytokine release, and reduced inflammatory and neuropathic pain. P2x7 deletion is beneficial in numerous pathophysiological and inflammatory conditions. Furthermore, alterations in bone formation (P2x7tm1Gab) and an anti-depressant-like profile (P2x7tm1Leq) were described. A floxed humanized P2X7 receptor knock-in mouse (P2x7tm1P2RX7tmDeq) showed an abnormal sleep pattern upon hP2X7R deletion.

Despite invaluable information derived from the early KO models, some caveats need to be considered: P2x7tm1Ckn and P2x7tm1Gab mice express alternative splice variants and incomplete receptor transcripts respectively. The P2X7 variant expressed in the P2x7tm1Ckn mouse is functional and highly expressed in T cells (Kaczmarek-Hajek, Lörinczi, Hausmann, & Nicke, 2012). Also, most published KO mice were generated using embryonic stem (ES) cells derived from 129 mouse strains and the existence and possible functional effects of...
129-derived passenger genes or mutations that remain upon backcrossing into other strains need to be considered, as shown for P2rx4tm1Rass mice (Er-Lukowiak et al., 2020), which contain the "gain-of-function" P2X7Leu451Pro variant. Finally, compensatory effects cannot always be excluded in non-conditional KO mice.

In 2007, the International Knockout Mouse Consortium (IKMC) formed with the aim to knockout each of the >20,000 protein-coding mouse genes in C57BL/6N-derived ES cells. To this end, the KOMP, EUCOMM, NorCOM, and TIGM programs coordinated their strategies to acquire, generate, archive, and distribute KO strains and disseminate the respective data. Within KOMP, two high-throughput gene targeting pipelines were established: (i) a bacterial artificial protein (BAC)-derived targeting vector-based approach (Valenzuela et al., 2003) to create null mutant alleles by preferentially deleting all sequences from the start ATG to the stop codon (used by the VelociGene group) and (ii) a gene-trapping approach (Skarnes et al., 2011) to create "ko-first/conditional-ready" alleles (Figure 4b) for tissue- or time-specific gene deletion (used by Children's Hospital Oakland Research Institute, Wellcome Trust Sanger Institute, University of California at Davis [KOMP-CSD]). The latter approach is also used in the EU-funded EUCOMM program. In the succeeding EUCOMM Tools program, inducible forms of Cre recombinase (CreERT2) together with an EGFP reporter are now knocked-in into genes with useful expression patterns such as P2rx7tm1(EGFP_CreERT2)Wtsi. Furthermore, standardized phenotyping projects were launched, and so far, data for P2x2 (non-significant), P2x4 (clavicle morphology

**FIGURE 4** Currently available P2X receptor mouse models according to the literature and Mouse Genome Informatics (MGI)/International Mouse Strain Resource (IMSR). (a) Strategies to target P2rx1–P2rx7 genes for the generation of knockout, knock-in, and transgenic mouse models. The nomenclature according to the current guidelines of the International Committee on Standardized Genetic Nomenclature for Mice is summarized in the inset and found on the mouse nomenclature home page (http://www.informatics.jax.org/mgihome/nomen/index.shtml). P2x4mCherryIN is not named accordingly, yet. Light yellow boxes represent exons, and black and coloured boxes represent introduced reporter/selection cassettes and/or cDNA. Circles behind the names indicate alleles that are only available in ES cells. In case of conditional strategies, only tm1a alleles ("ko-first") are shown. These can be further modified as described in (b). Further knockout strains are available from Taconic (deleted exons in brackets) for P2x1 (2–7), P2x4 (2–4), P2x5 (1), P2x6 (1–2), and P2x7 (2–3) and from TIGM (gene trap vector insertion in brackets) for P2x1 (IST14381H9), (IST12457B12), and P2x3 (IST10786C2). In addition, P2x2tm1a(MIPCH), P2x4gt (GT5743078L8), and Gt (ROSA)26Sor tm108RNAiP2x7x9innu are available. Targeted reporter-tagged insertion with conditional (b) potential (ko-first, conditional ready) and reporter-tagged deletion alleles (c) and the respective nomenclature. Derivative alleles can be obtained through recombinase (Flp or Cre, as indicated)-mediated changes (https://mpii.github.io/IKMC-knowledgebase/2010/08/24/what-are-the-allele-types.html). The lacZ reporter is supposed to be spliced to the upstream exon 1 (a). However, skipping of lacZ (b) and splicing to the downstream (critical) exon (resulting in functional WT or hypomorph) cannot be excluded and needs to be experimentally determined. The critical exon is supposed to produce a frameshift mutation upon deletion. Note that tm1e represents an unplanned by-product of the original targeting strategy in which the 3'loxP site was lost during recombination but which might still be useful. For detailed information and references, see Kaczmarek-Hajék, Lörinczi, Hausmann, and Nicke (2012), Nicke, Grutter, and Egan (2018), http://www.informatics.jax.org/, and http://www.findmice.org/
and heart weight), P2X5 (gait and preweaning lethality), P2X6 (cholesterol level and body fat), and P2X7 receptors (cataract and eye morphology) are available at the International Mouse Phenotyping Consortium (IMPC) website (www.mousephenotype.org).

Additionally, P2X reporter mice that express soluble fluorescent reporter proteins or fluorescent protein-tagged receptors are becoming available (Figure 4A). While both the BAC transgenic Tg(P2rx4-tdTomato)1Khakh (expressing soluble tdTomato) and the P2rx4mCherryRN knock-in mouse (conditionally expressing mCherry-tagged P2X4) reliably reported P2X4 receptor expression (Bertin et al., 2020; Xu et al., 2016), two BAC transgenic P2X7 receptor reporter mice (Tg(P2rx7-EGFP)FY174Gsat and Tg(RP24-114E20–P2X7–His-StrepEGFP)Ani) (expressing soluble and P2X7-fused EGFP, respectively) show highly divergent expression patterns (Kaczmarek-Hajek et al., 2018), further demonstrating the need for careful characterization of mouse models, in particular those generated in high-throughput approaches. Most recently, a knock-in P2X2Cre mouse was described, which upon crossing with Cre-sensitive reporter mice reveals P2X2 receptor expression (Kim et al., 2020).

5 | CLONED PRIMITIVE P2X RECEPTORS

The cloning of P2X receptors from primitive organisms including amoeba and algae demonstrates the early utilization of ATP as a fast transmitter molecule (Fountain & Burnstock, 2009). Those cloned to date have low protein sequence homology with mammalian P2X receptors, typically 20–40%, and as such, a different nomenclature has been devised from that of mammalian P2X receptors. This system includes a prefix of an italicized short form of the species the receptor was cloned from, and in cases where multiple subtypes are identified, a letter is denoted in subscript (e.g., DdP2xA, Dictyostelium discoideum P2X receptor subtype A). The National Centre for Biotechnology (NCBI) accession number is given for each cloned receptor in parenthesis as they are introduced in the following sections. Bioinformatic analysis predicts further primitive P2X receptors (Fountain & Burnstock, 2009), but this section describes those that have been cloned and are reported to form functional P2X receptors.

D. discoideum is a soil-living amoeba that transitions to a multicellular developmental life cycle. Five P2X receptors have been cloned. DdP2xA (XM_640286), DdP2xB (XM_638738), DdP2xC (XM_638739), DdP2xD (XM_631676), and DdP2xE (XM_631865). DdP2xC does not form functional channels following heterologous expression in HEK293 cells or X. laevis oocytes (Fountain et al., 2007). DdP2xO forms functional channels under low external Na+ conditions (Baines et al., 2013). The functional receptors display a rank order in sensitivity to ATP of DdP2xA (EC50 97 μM) > DdP2xB (EC50 266 μM) > DdP2xC (EC50 511 μM). For DdP2xA, β,γ-imido-ATP (EC50 15 μM) and αβ-methylene ATP (EC50 95 μM) are full agonists and BzATP is a weak partial agonist (25% activation at 3 mM). β,γ-Imido-ATP is a full agonist at DdP2xB receptors (EC50 85 μM) and weak partial agonist at DdP2xC receptors (22% activation at 3 mM). DdP2xA, DdP2xB, and DdP2xC receptors are insensitive to suramin, PPADS, and TNP-ATP but inhibited by Cu2+ (DdP2xA, IC50 40 nM; DdP2xB, 85% inhibition at 100 nM; DdP2xC, 30% inhibition at 100 nM; and DdP2xO, 70% inhibition at 100 nM).

Further P2X receptors with variable sensitivities to known P2X receptor ligands have been described in Schistosoma mansoni, Ostreococcus tauri, Monosiga brevisculis, Hypsibius dujardini, Boophilus microplus, and Lymnaea stagnalis (Fountain, 2013).

6 | P2X1 RECEPTOR

6.1 | P2XR1 gene and structure

The P2RX1 gene (ENSG00000108405) is on human chromosome 17p13.3, is 2,662 bp long, has 12 exons, and encodes a protein of 399 amino acids. The Ensembl Gene database lists four splice variants and 262 species orthologues. In common with all other P2X receptor subtypes, 102 species orthologues are present in placental mammals and they are also present in birds, reptiles, and fish, but not in Caenorhabditis elegans, Drosophila melanogaster, and Saccharomyces cerevisiae.

The homomeric P2X1 receptor is a rapidly desensitizing, non-selective, cationic channel, with a relatively high permeability to Ca2+ (Egan & Khakh, 2004). Recombinant P2X1 subunits also form functional heteromultimers with the P2X2, P2X4, and P2X5 subunits, but this has not as yet been reported in vivo, with the exception of P2X1/5 (see Kennedy, 2015).

6.2 | Expression

P2RX1 mRNA and P2X1 receptor protein are widely expressed throughout the body (Burnstock & Knight, 2004; Kennedy, 2015). P2X1 is the predominant P2X subunit present in most smooth muscle tissues, including vas deferens, arteries, and urinary bladder. Recently, Mahaut Smith, Evans, and Vial (2019) created a P2X1 receptor-eYFP knock-in mouse, enabling receptor expression to be viewed in live cells. Confirming earlier reports, P2X1 receptor-eYFP fluorescence was seen in urinary bladder and arterial smooth muscle cells, platelets, and megakaryocytes but was absent from the CNS. Furthermore, the receptor is highly mobile within the plasma membrane and likely present in lipid rafts, cholesterol-rich microdomains that are involved in receptor signaling and trafficking.

6.3 | Neurotransmission

P2X1 receptors mediate the actions of ATP when it is released as an excitatory co-transmitter with noradrenaline from sympathetic, and with ACh from parasympathetic nerves. Initial evidence depended upon P2X1 receptor desensitization by αβ-methylene ATP (αβ-meATP) or inhibition by antagonists, but the clearest
evidence is provided by gene KO (see Kennedy, 2015, and references therein). This greatly decreased the amplitude of sympathetic contractions of mouse vas deferens and was associated with a 90% fall in fertility. Simultaneous KO of α1A-adrenoceptors caused total infertility. Thus, P2X1 receptors clearly play a crucial role in male reproductive function. Sympathetic, purinergic co-transmission in arteries mediates vasoconstriction, but its contribution to mean arterial BP is unclear.

Parasympathetic nerves mediate contraction of urinary bladder detrusor smooth muscle, causing voiding of urine. In most species, atropine only partly inhibits these contractions and P2X1 receptor KO abolished the remaining response. Interestingly, P2X1 receptor antagonists failed to mimic the effect of P2X1 receptor KO, and it was suggested that ATP may act at both the homomeric P2X1 receptor and at the P2X1/4 receptor heteromer to elicit urinary bladder contraction (Kennedy, Tasker, Gallacher, & Westfall, 2007).

### 6.4 Thrombosis

P2X1 receptors mediate Ca²⁺ influx in platelets, but P2X1 receptor KO mice do not show spontaneous bleeding or increased bleeding time (Hechler et al., 2003). Fewer KO mice died, however, in an in vivo model of acute obstruction of the lung microcirculation. Furthermore, thrombi formed by localized damage to arterioles were smaller and easily dispersed. Thus, platelet P2X1 receptors may contribute to thrombi formation, particularly in arterioles, which are narrow and associated with a high shear stress.

### 6.5 Dysfunctional urinary bladder

Atropine abolishes neurogenic contractions of the healthy urinary bladder in humans, but atropine-resistant contractions appear with increasing age and in chronic disorders, such as interstitial cystitis, idiopathic detrusor instability, and overactive bladder syndrome. They are abolished in vitro by prolonged exposure to α,β-meATP, indicating mediation by P2X1 receptors, though this has yet to be been confirmed using P2X1 receptor antagonists (see Kennedy, 2015).

### 6.6 Inflammation

ATP released by stressed or damaged cells, or in response to inflammatory stimuli, acts via P2X4, P2X7, P2Y1, P2Y2 and P2Y6 receptors as a damage-associated molecular pattern (DAMP) signalling molecule to elicit pro-inflammatory responses in macrophages and neutrophils (Di Virgilio, Sarti, & Coutinho-Silva, 2020). Lecut et al. (2012) reported that P2X1 receptor KO increased mortality due to LPS-induced endotoxemia, but Maitre et al. (2015) saw a decrease, while there was no difference in the mortality rate from septic shock induced by uropathogenic Escherichia coli (Greve et al., 2017). The reasons for this variability are unclear but may reflect differences in the serotype of the pathogenic stimulus used.

Platelets also contribute to inflammation by facilitating immune cell recruitment and activation. In a mouse model of colitis, platelet depletion or P2X1 receptor KO caused intestinal bleeding, leading to macrocytic regenerative anaemia, whereas neutrophil depletion reduced blood loss (Wera et al., 2020). Thus, platelet and neutrophil P2X1 receptors may have protective roles in the inflamed intestine.

### 6.7 P2RX1 single nucleotide polymorphisms in cancer

The HIVE Lab database lists 86 unique P2RX1 single nucleotide polymorphisms (SNPs) in cells from multiple types of cancer that change the P2X1 receptor protein sequence. Whether these contribute to the development and/or maintenance of cancer is unknown, but many are predicted to be “probably damaging.” A significant reduction in P2RX1 mRNA expression was identified in several cases, but it is unclear if this is a cause or effect of the cancer.

### 7 P2X2 RECEPTOR

#### 7.1 The P2RX2 gene

The first PRX2 cDNA encoding the rP2X2 subunit protein (UniProt ID P49653.1) was expression cloned from pheochromocytoma cells using X. laevis oocytes (North, 2002). The Ensembl database locates the hP2RX2 gene (ENSG00000187848) on chromosome 12 (between 132,618,776 and 132,622,388 bp) and predicts eight splice variants. The P2RX2 genomic structure consists of 11 exons and 10 introns and is highly conserved among human and rat.

#### 7.2 Homotrimeric and heterotrimeric P2X2 receptor proteins

P2X2 receptor subunits assemble during their endoplasmic reticulum-bound synthesis into homotrimers (Aschrafi, Sadtlar, Niculescu, Rettinger, & Schmalzing, 2004; Nicke et al., 1998). The contacts between the subunits relevant for trimerization are located in the ectodomain, while the TMs support assembly by restricting the folding space (Duckwitz, Hausmann, Aschrafi, & Schmalzing, 2006). P2X2 receptor subunits are co-expressed with other P2X subtypes in many cell types; in recombinant systems, they can co-assemble to functional and stable heterotrimers, such as P2X2/1, P2X2/3, P2X2/5, and P2X2/6 receptors (Hausmann, Kless, & Schmalzing, 2015).

There is no direct X-ray or cryo-EM structure of a P2X2 receptor available, but X-ray templates from the zfP2X4 receptor (see Section 3) enabled building P2X2 receptor homology models, which proved to be reliable. Achievements of these models include (i) understanding P2X2 receptor channel gating; (ii) localization of
potency-determining residues of the P2X2 receptor antagonist NF770 (a suramin derivative) by homology docking; (iii) disclosure of lateral fenestrations as ion access pathways to the channel pore; and (iv) identification of ionic coordination of ATP\(^{4-}\) into its binding pocket as an opening mechanism to break a salt bridge that stabilizes the closed state (Hausmann, Kless, & Schmalzing, 2015). The subtype-specific signatures of the homotrimeric P2X2 receptor channel are (i) fast activation by external ATP; (ii) virtually no activation by up to 300-\(\mu\)M external \(\alpha\beta\)-meATP; and (iii) among all P2X receptor subtypes, the most stable steady-state current during prolonged ATP exposure, with slow or no desensitization (North, 2002). The main active form of ATP at the P2X2 receptor is free ionic ATP (ATP\(^{4-}\); \(E_{C50}\) 2.0 ± 0.7 \(\mu\)M in divalent-free solution); the \(\text{Mg}^{2+}\)-complexed form \(\text{MgATP}^{2-}\) binds with much lower affinity and is thus largely ineffective in opening the P2X2 receptor (Li, Silberberg, & Swartz, 2013).

### 7.3 P2X2 receptor expression and physiological functions

P2RX2 mRNA and P2X2 receptor protein are expressed abundantly throughout the body on neurons and non-neuronal cells (Cockayne et al., 2005). The Human Brain Atlas (http://proteinatlas.org) points to a particularly high \(2RX2/P2X2\) receptor expression in the hippocampal formation. Compared with the widespread expression in the nervous system, the behavioural phenotype in P2X2 receptor KO mice is remarkably inconspicuous in terms of general excitability of the CNS and sensory and motor function (Cockayne et al., 2005). Essential physiological P2X2 receptor functions are their contribution to the sensitivity of the carotid body to hypoxia by stimulating afferent fibres of the sinus nerve (Rong et al., 2003) and their involvement in taste perception in an epithelial-to-neuronal mode of signalling. Exposure of oral taste receptor cells to taste stimuli releases ATP that activates P2X2 and P2X3 receptors, which are co-expressed in the taste buds that innervate the tongue (Cockayne et al., 2005). P2X2/P2X3 receptor double-KO mice are taste blind to all taste stimuli, P2X2/\(\beta\)-meATP with the typical inward currents, although P2X2

### 8 P2X3 AND P2X2/3 RECEPTORS

#### 8.1 P2rx3 and P2RX3R genes and the respective homomeric and heteromeric proteins

The ensemble database reports \(mP2rx3\) (ENSMUSG00000027071), \(rP2rx3\) (ENSRNOG0000008552), and \(hP2RX3\) (ENST00000640659) cDNAs encoding full receptor proteins. The \(mP2rx3\) has two and the \(hP2RX3\) only one protein-coding splice variant. The \(rP2X3\) receptor protein was cloned from dorsal root ganglia (DRGs), which when expressed in \(X.\) \(laevis\) oocytes, yielded a channel responding to ATP with a rapidly desensitizing current (Chen et al., 1995). Soon afterwards, it was found that the co-expression of \(rP2X3\) with \(rP2X2\) receptors yielded ATP-activated currents that slowly desensitized and resembled those recorded in rat nodose ganglia (Lewis et al., 1995). Apparently, sensory neurons of the DRG possess a mixture of \(P2X3\) and \(P2X2/3\) receptor channels, while nodose ganglia possess only \(P2X2/3\) receptors. Both \(P2X3\) and \(P2X2/3\) receptors respond to the agonist \(\alpha\beta\)-meATP with the typical inward currents, although \(P2X2\) receptors are insensitive to \(\alpha\beta\)-meATP. Originally, it was assumed that \(P2X2/3\) receptors consist of an obligatory combination of two \(P2X3\) and one \(P2X2\) subunit (Jiang et al., 2003), but later, an inverse combination of the two types of subunits \([P2X2]_2[P2X3]_1\) was shown to be also functional in expression systems for recombinant receptors (Kowalski et al., 2015).

#### 8.2 P2X3 and P2X2/3 receptor distribution and function

In addition to postsynaptic P2X3 and P2X2/3 receptors located at the cell bodies of sensory neurons, presynaptic P2X3 and P2X2/3
receptors have a facilitatory role to enhance glutamatergic neurotransmission from the central terminals of sensory neurons onto the cell bodies of spinal cord afferent neurons (Khakh & North, 2012). The regulation of P2X3 and P2X2/3 receptor expression in pathophysiology is complex. Both up-regulation and down-regulation of individual receptor subunits have been documented in various experimental models (Bernier, Ase, & Seguela, 2018; North & Jarvis, 2013). This variability is likely dependent on specific contextual influences, including neuroanatomical structure and biochemistry. The ability of ATP to evoke ectopic neuronal hypersensitivity may not be solely dependent on intrinsic P2X3 or P2X2/3 receptor activation, since functional interactions with other P2 receptors, ligand-gated ion channels, and multiple signalling pathways have been described (Bernier, Ase, & Seguela, 2018).

Important insights regarding the physiological roles of P2X2, P2X3 and P2X2/3 receptors were gained through the functional analysis of transgenic and transient gene disrupted (i.e., P2X3 anti-sense) mice (North & Jarvis, 2013). Genetic disruption of each of these individual P2X receptors resulting in a complete loss of receptor expression has been shown to reduce sensory nerve function and a concomitant diminution of nociceptive and hyperactive bladder responses (Ford & Undem, 2013; North & Jarvis, 2013). Transgenic mice lacking both P2X2 and P2X3 receptors also show alterations in taste sensitivity to bitter and sweet substances (Finger et al., 2005). Based on the known physiological roles of P2X3 and P2X2/3 receptors, their expression on taste buds (Finger et al., 2005) and the phenotype of double-KO mice lacking both P2X2 and P2X3 receptors, gefapixant-mediated dysgeusia is likely mediated by block of the heteromeric P2X2/3 receptors (Garceau & Chauriet, 2019). First-generation non-nucleoside P2X3 receptor antagonists show little selectivity in blocking homomeric P2X3 receptors and heteromeric P2X2/3 receptors (North & Jarvis, 2013). However, more recently discovered P2X3 receptor antagonists, including the imidazopyridine, BLU-5937, have stereoselective preferential affinity at P2X3 receptors, with several orders of magnitude lower affinity at P2X2/3 receptors (Garceau & Chauriet, 2019). BLU5937 is currently in a proof-of-concept trial for chronic cough.

8.3 | P2X3 receptor antagonists in clinical concept trials

Studies using non-selective antagonists or agonist-induced down-regulation of P2X3 receptors provided preliminary evidence for the roles of these receptors in sensory systems (Jarvis & Khakh, 2009). Subsequently, in vivo studies using selective antagonists for P2X3 and P2X2/3 receptors generated evidence that blocking these receptors leads to diminished nociceptive sensitivity in a variety of experimental pain models, reduced bladder reflexes and elevated bladder volume thresholds, and reduced airway sensitivity in preclinical cough models (Ford & Undem, 2013; North & Jarvis, 2013).

Gefapixant (AF-219, MK-7264), the potent and reversible non-competitive antagonist of P2X3 receptors is approximately threefold less potent at P2X2/3 receptors (Richards, Gever, Ford, & Fountain, 2019). Gefapixant and closely related diaminopyrimidine class structural analogues inhibit P2X3 receptor-dependent action potentials in afferent neurons innervating peripheral tissues in a variety of nociceptive, urological, and respiratory models (Ford & Undem, 2013; Richards, Gever, Ford, & Fountain, 2019).

Gefapixant is orally bioavailable, peripherally restricted, and has suitable drug-like properties enabling exploration of its therapeutic potential in humans (Ford & Undem, 2013). A consistent tolerability finding for gefapixant-treated patients is a high prevalence of altered taste sensitivity (dysgeusia; Smith et al., 2020). This appears to be dose dependent, indicating a potential for optimization of a dose to maintain anti-tussive efficacy, while minimizing dysgeusia (Smith et al., 2020).
Homotrimeric and heterotrimeric P2X4 receptors also undergo rapid constitutive and agonist-induced internalization into early endosomes and lysosomes and subsequent reinsertion into the plasma membrane (Bobanovic, Royle, & Murrell-Lagnado, 2002). Internalization of P2X4 receptors is clathrin- and dynamin-dependent and determined by the C-terminal interacting with adapter protein 2 (AP2); mutation of either the endocytic motif or the Tyr binding pocket of AP2 leads to accumulation of functional receptors in the plasma membrane. Native P2X4 receptors in cultured rat microglia, macrophages, and vascular endothelial cells are localized predominantly in lysosomes, where they retain their functionality and subsequently move out to the plasma membrane. This finding led to speculation about their intracellular functions (Kaczmarek-Hajek, Lörinczi, Hausmann, & Nicke, 2012).

### 9.3 Distribution and function

P2X4 receptors are abundantly expressed in neurons and glial cells of several brain regions, including olfactory bulb, cerebral cortex, subcortical telencephalon, cerebellum, hypothalamus, thalamus, midbrain, hindbrain, and ventricular structures. These receptors are also present in spinal cord microglia, peripheral neurons, including somatosensory cortical, nodose ganglion, trigeminal, vestibular ganglion, and spinal cord neurons, in addition to Schwann cells. In the mammalian retina, the receptor was identified in both neurons and glia (Montilla, Mata, Matute, & Domercq, 2020). The neuroendocrine cells of the hypothalamus and pituitary gland and the endocrine cells of the thyroid and adrenal glands also express P2X4 receptors (Bjelobaba, Janjic, & Stojilkovic, 2015). In the cardiovascular system, they are located in cardiac and vascular smooth muscle cells and endothelial cells (Ralevic, 2015).

Numerous studies have shown a role for P2X4 receptors in allodynia associated with chronic neuropathic pain, a persistent pain arising from changes in spinal cord processing pathways (Inoue, 2019). After nerve injury, overexpression of P2X4 receptors in Schwann cells was reported to promote motor and sensory functional recovery and remyelination via brain-derived neurotrophic factor (BDNF) secretion. Furthermore, the P2X4 receptor has a role in neuroinflammation, the complex biochemical, and cellular response occurring during infections of the brain and the spinal cord, with the participation of microglia, astrocytes, and endothelial cells. Spinal cord injury, brain ischaemia, and trauma increase P2X4 receptor expression in microglial cells, which could be involved in inflamed lesions in the brain that persist for days/weeks after an ischaemic stroke. The P2X4 receptor may also play a role in neurodegenerative diseases, such as Parkinson’s disease, Alzheimer’s disease (AD) and multiple sclerosis, as they are associated with neuroinflammation that is accompanied by P2X4 receptor-dependent microglia activation. Expression of P2X4 receptors is up-regulated in activated microglia from rats with experimental autoimmune encephalomyelitis (a model of amytrophic lateral sclerosis) and in human multiple sclerosis optic nerve samples, and they appear to facilitate repair response after demyelination (Montilla, Mata, Matute, & Domercq, 2020). Finally, activated P2X4 receptors stimulate electrical activity, Ca\(^{2+}\) signalling, and neurohormone secretion in neuroendocrine cells (Bjelobaba, Janjic, & Stojilkovic, 2015).

### 9.4 Transgenic and KO models (see also Section 4)

A transgenic mouse model overexpressing the human P2X4 subunit exhibited increased contractility of cardiomyocytes and greater global contraction performance in intact heart compared with wild-type (WT) animals (Hu et al., 2001). Overexpression of human P2X4 receptors in a calsequestrin transgenic mouse model of cardiomyopathy significantly delayed heart failure progression and increased life expectancy by more than twofold (Yang, Sonin, Jones, Barry, & Liang, 2004). The P2X4 receptor also contributes to the control of large vessel tone through endothelial-dependent NO release and arterial smooth muscle relaxation. Consistently, P2X4 receptor KO mice and human carriers of low functional 315Cys-P2X4 receptors have raised BP (Braganca & Correia-de-Sa, 2020).

### 10 P2X5 RECEPTOR

#### 10.1 P2RX5 gene, splice variants, and SNPs

The human P2X5 gene (ENSG00000083454), located on 17p13.2, occurs as two alleles: T allele and G allele. The T allele leads to mature transcription of a full-length P2X5 subunit of 444 amino acids and assembly of functional P2X5 receptor ion channels (Kotnis et al., 2010). The G allele appears in samples of human genomic DNA, but not in other mammals (Kotnis et al., 2010). The 3’splice site (GGTCGGggtg) of exon 10 contains gg on the intronic side rather than gt, at which RNA splicing occurs (Bo et al., 2003). This SNP results in a shorter subunit, which lacks the 22 amino acids encoded by exon 10 (Duckwitz, Hausmann, Aschrafi, & Schmalzing, 2006; Le, Paquet, Nouel, Babinski, & Seguela, 1997). Assemblies of the exon 10-deleted hP2X5 receptor are retained in the cytosol by the endoplasmic reticulum (Duckwitz, Hausmann, Aschrafi, & Schmalzing, 2006).

#### 10.2 P2X5 receptor protein

rP2X5 and mP2X5 subunits share 95% homology over their 455 amino acid length, and 62% homology with the full-length hP2X5 subunit. rP2X5 and mP2X5 receptor channels are remarkable for producing very small currents to supramaximal ATP concentrations, around 5% of the amplitude of inwards currents generated under equivalent conditions by other P2X receptors expressed in cell lines or X. laevis oocytes (Collo et al., 1996). Light was shed on the cause of the small ATP responses, using a series of chimeric P2X5 receptors bearing rat peptide sequences replaced with human equivalents (Sun et al., 2019). Two rP2X5 receptor-chimeras yielded considerably larger ATP responses: rP2X5 receptor-chimera 3, Ile\(^{50}\)-Arg\(^{14}\) (72 pA·pF\(^{-1}\)); rP2X5 receptor-chimera...
5, Leu^{171}-Lys^{205} (162 pA·pF^{-1}); compared with rP2X5 receptor-WT (2 pA·pF^{-1}). Single-substitution experiments subsequently revealed that any one of three mutations (Ser191Phe, Phe195His, and Val67Ile) significantly improved functionality of rP2X5 receptors by improving ATP binding at its docking site (Sun et al., 2019).

When stimulated by ATP, P2X5 receptors function as desensitizing, non-selective cationic channels ($P_{Ca}/P_{Na} = 1.5$). Unlike other P2X receptors, the P2X5 receptor is also permeable to chloride ions ($P_{Cl}/P_{Na} = 0.5$) (Bo et al., 2003).

### 10.3 | P2X5 receptor function

Functional P2X5 receptors may play a supporting role in the inflammatory response. Gene deletion of P2X5 receptors ($mP2RX5^{-/-}$) decreased inflammatory bone loss in the parietal calvarium (skull), in vivo, without affecting normal bone development and homeostasis (Kim et al., 2017). Additionally, expression levels of pro-inflammatory IL-1β, IL-6, IL-17a, and TNF-α are significantly lower in P2x5^{-/-} mice compared with WT mice (Kim et al., 2018).

### 11 | P2X6 RECEPTORS

#### 11.1 | P2RX6 gene and P2X6 receptor protein

The encoding DNA for the protein subunit has been identified in the human genome (ENSG00000099957) at 22q11.21. P2X6 receptors are ATP-gated ion channels when fully glycosylated. In 25 years, only two groups have succeeded in characterizing functional rP2X6 receptors (Collo et al., 1996; Jones et al., 2004). In both studies, around 5% of transfected HEK293 cells yielded agonist responses to ATP and other nucleotides, and P2X6 receptors functioned as desensitizing, non-selective cationic channels.

N-linked glycosylation of ion channels can affect subunit folding, oligomeric assembly, trafficking to the membrane, agonist binding, and channel opening. The extracellular domain of P2X6 receptors contains the NXS/T glycosylation motif at three sites, with asparagine (N) residues at positions 157, 187, and 202 of the rat isoform (Jones et al., 2004; Newbalt et al., 1998; Rettinger, Aschraft, & Schmalzing, 2000). Functional and non-functional rP2X6 receptor proteins extracted from HEK293 cells were discriminated by the molecular mass of epitope-tagged P2X6 subunits of 70- and 60-kDa MW, respectively (Jones et al., 2004). Treatment with N-glycosidase F reduced the molecular masses to 50 kDa, which is the expected size of the non-glycosylated P2X6 protein subunits. Thus, the efficiency of subunit glycosylation may hold the key to whether or not P2X6 receptors express functionally.

### 11.2 | P2X6 receptor distribution and function

There has been renewed interest in P2X6R expression of P2X receptors, based on two observations. Firstly, glycosylation of P2X6 subunits may be more efficient in native cell types compared with expression systems, producing the 70-kDa P2X6 subunits identified in adult midbrain, atrium, kidney, thymocytes, and urinary bladder (Jones et al., 2004). Secondly, non-glycosylated P2X6 receptors were translocated through the nuclear pore complex to the nucleus of mouse hippocampus neurons, where they interacted with the splicing factor (SF3A1), to reduce the incidence of mRNA splicing (Diaz-Hernandez, Sebastian-Serrano, Gomez-Villafuertes, Diaz-Hernandez, & Miras-Portugal, 2015). A recent clinical study has implicated P2X6 receptor overexpression in the progression and poor prognosis of renal cell cancer in human patients (Gong et al., 2019).

### 12 | P2X7 RECEPTORS

#### 12.1 | The P2RX7 gene, splice variants, and SNPs

The human P2X7 receptor is encoded by the hP2RX7 gene (ENSG000000899041) on the long arm of chromosome 12, at 12q24.31 (Bartlett, Stokes, & Slyuter, 2014), close to the hP2RX4 gene (12.q24.32), while mP2rx7 is located on chromosome 5. Several non-synonymous, intronic, or missense SNPs have been reported in the hP2RX7 gene. A number of P2X7 receptor isoforms derived from alternative splicing were identified both in humans and in rodents (Bartlett, Stokes, & Slyuter, 2014). Some variants are expressed and functional, for example, human P2X7B receptor, and mouse and rat P2X7 receptor variant “k.”

Some SNPs occurring in the coding region cause gain or loss of receptor function and are variably associated to different disease conditions. Linkage studies suggested that the SNP rs2230912 coding for Gln460Arg-P2X7R is connected with major depression and bipolar disorder, although this has been questioned by others (Illes, Rubini, Huang, & Tang, 2019).

#### 12.2 | The P2X7 receptor protein

The P2X7 receptor has the lowest affinity for ATP among all P2 receptors, a feature that has often raised doubts on its pathophysiological role. However, it is now clear that at sites of inflammation or in cancer, the local extracellular ATP concentration can rise to levels close to those needed to stimulate the P2X7 receptors (Di Virgilio, Schmalzing, & Markwardt, 2018). In addition, some inflammatory factors may act as PAMs, thus lowering the ATP threshold for P2X7 receptor activation (Di Virgilio, Sarti, Falzoni, De Marchi, & Adinolfi, 2018).

It was suggested about 20 years ago that some P2X receptor channels (P2X2, P2X4, and P2X7) exhibit progressive dilation during long-lasting stimulation by ATP and that the generated pore is permeable to high MW cationic dyes, such as NMDG, Yo-Pro, ethidium, or propidium iodide (Di Virgilio, Sarti, Falzoni, De Marchi, & Adinolfi, 2018). However, later, it was shown that this interpretation of the experimental data obtained by reversal potential measurements...
is probably misleading. Participation of associated channel-forming proteins, such as pannexin-1 or connexin-43, has been suggested but convincing evidence now supports the view that the P2X7 receptor itself has the ability to form a large-conductance pore in the absence of any significant dilatation. Simply, the P2X7 receptor channel allows the passage of large cationic molecules immediately from its initial activation, but at a much slower pace than that of the small cations Na⁺, K⁺, and Ca²⁺ (Di Virgilio, Sarti, Falzoni, De Marchi, & Adinolfi, 2018).

An early argument brought up to support the assumed dilatation of P2X7 receptors was the facilitation of P2X7 receptor currents during long-lasting or repetitive application of ATP or BzATP (Surprenant, Rassendren, Kawashima, North, & Buell, 1996). However, this was later shown to be independent of the entry of cationic molecules via the receptor channel and rather caused by a Ca²⁺/calmodulin-dependent current facilitation through some P2X7 receptor orthologues (rat, but not human) (Roger, Gillet, Baroja-Mazo, Surprenant, & Pelegrin, 2010) or the secondary activation of a chloride current, for example, in macrophages (Janks, Sprague, & Egan, 2019).

### 12.3 | P2X7 receptors in the immune system

The P2X7 receptor is widely expressed by myeloid and lymphoid immune cells, as well as by mast cells (Di Virgilio, Dal Ben, Sarti, Giuliani, & Falzoni, 2017). Platelets also express P2X7 receptors, albeit at low level. The best characterized immune response associated with P2X7 receptor stimulation is activation of the leucine-rich repeat, pyrin domain-containing 3 (NLRP3) inflammasome, and IL-1β secretion, but several other key immune responses (e.g., release of additional pro-inflammatory or anti-inflammatory cytokines or chemokines, generation of reactive oxygen species (ROS), promotion of chemotaxis, stimulation/inhibition of phagocytosis, destruction of intracellular pathogens, and formation of multinucleated giant cell at inflammatory granulomas) are promoted by P2X7 receptor stimulation. Due to the relevance of the P2X7 receptor in macrophage responses, the association of major infectious diseases with P2RX7 polymorphisms has been widely investigated but with inconsistent results.

The P2X7 receptor has a special place in the overall mechanism of IL-1β secretion since its gating by extracellular ATP allows the efflux of large amounts of cytosolic K⁺ that in turn drives NLRP3 assembly and caspase-1 activation. In fact, the P2X7 receptor is the most potent plasma membrane receptor triggering pro-IL-1β processing and release (Di Virgilio, Dal Ben, Sarti, Giuliani, & Falzoni, 2017) and thus is a crucial initiator of inflammation. P2X7 receptor KO mice are less prone to initiate inflammation in response to a variety of stimuli. Secretion of mature IL-1β is severely reduced, and as a consequence, initiation of the cascade of inflammatory cytokines is also impaired (Solle et al., 2001).

Human neutrophils express functional P2X7 receptors coupled to NLRP3 activation (Karmakar, Katsnelson, Dubyak, & Pearlman, 2016). In these cells, P2X7 receptor activity is required for efficient clearance of Streptococcus pneumoniae-sustained bacterial infection (Karmakar, Katsnelson, Dubyak, & Pearlman, 2016). Dendritic cells (DCs) are the immune cell types that express the highest level of P2X7 receptors. Different responses are dependent on P2X7 receptor function in DCs, most notably antigen presentation (Mutini et al., 1999). It is highly likely that the P2X7 receptor is a key component of the DAMP-sustained stimulatory circuit whereby adjuvants potentiate antigen presentation (Di Virgilio, Dal Ben, Sarti, Giuliani, & Falzoni, 2017).

Very recently, P2X7 receptors were shown to be necessary to establish long-lived memory CD8⁺ cells and thus play a major role in immunological memory (Borges da Silva et al., 2018). Certain NK cell subtypes also express high levels of P2X7 receptors that, as for CD8⁺ T lymphocytes, have a major role in supporting energy metabolism and maintaining these lymphoid cells fit. In the gut, P2X7 receptors are expressed by T follicular helper cells (Tfh) where they participate in Tfh–B-cell communication (Perruzza et al., 2017). P2X7 receptor activity is understood to be necessary for the differentiation of IL-17-producing T lymphocytes in models of experimental arthritis (Fan et al., 2016) and for the induction of IL-23-dependent psoriatic dermatitis (Diaz-Perez et al., 2018).

The P2X7 receptor is an important link between inflammation and coagulation since stimulation of macrophage and DC P2X7 receptors drive a large microvesicle-mediated release of tissue factor (TF), the initiating agent of the extrinsic coagulation pathway (Baroni et al., 2007). The P2X7 receptor is one of the most potent triggers for the release of exosomes and plasma membrane-derived microvesicles containing a vast array of intracellular components and exposing a variety of surface markers (Slyuter, 2017). Furthermore, stimulation of P2X7 receptors promotes vascular endothelial growth factor (VEGF) release and supports angiogenic activity in vivo (Adinolfi et al., 2012). Participation of the P2X7 receptors in cancer growth and metastasis is increasingly recognized (Di Virgilio, Schmalzing, & Markwardt, 2018).

### 12.4 | P2X7 receptors in peripheral organs

Outside the immune system, the P2X7 receptor is expressed by many different cell types, such as keratinocytes, corneal cells, hepatocytes, intestinal epithelial cells, vascular endothelial cells, retinal ganglion cells, fibroblasts, osteoclasts, osteoblasts, vascular smooth muscle, and skeletal muscle (Bartlett, Stokes, & Slyuter, 2014; Slyuter, 2017). It can be safely concluded that P2X7 receptors are ubiquitously expressed throughout the body, albeit to different levels. While the role of the P2X7 receptors in the immune system is well established, in other tissues, it is more elusive.

### 12.5 | P2X7 receptors in the CNS

The mammalian CNS consists of neuronal and non-neuronal cells. The latter comprise mainly of glia (astrocyte-like cells, oligodendrocytes, and microglia) and ependymal cells. Microglia are resident
tau-induced activation of the toll-like and P2X7 receptors by DAMPs (ATP itself is the glial signalling molecules (Illes, Verkhratsky, & Tang, 2019). Effects attributed previously to the activation of neuronal P2X7 receptors are now thought to be indirect, mediated by the release/outflow of giotransmitters, or other types of glial signalling molecules (Illes, Verkhratsky, & Tang, 2019).

12.6 | Involvement of P2X7 receptors in neurological and psychiatric illnesses

Although neurodegenerative illnesses have specific and distinct causative factors, they generate also an additional neuroinflammatory component that aggravates the primary condition. P2X7 receptors of glial cells are intimately involved in neuroinflammation, and therefore, P2X7R antagonists have a favourable symptomatic impact in case of these illnesses. Glial (especially microglial) P2X7Rs are stimulated by large concentrations of ATP released from CNS cells under noxious conditions, during both acute injury (trauma, hypoxia/ischaemia, and epilepsy-induced seizures) and chronic neurodegenerative conditions (AD, Parkinson’s disease, amyotrophic lateral sclerosis, and multiple sclerosis) (Burnstock, Krügel, Abbracchio, & Illes, 2011).

Epilepsy is typically thought to be the result of an enduring imbalance between excitation and inhibition in the brain (Engel, Alves, Sheedy, & Henshall, 2016). A major cause of long-lasting epileptic seizures termed “status epilepticus” (SE) is caused by the increased release of ATP. Kainic acid injection into the nucleus amygdala of mice induced seizure-like EEG activity; P2X7 receptor antagonists reduced electrographic seizures and cortical cell death. Conversely, when SE was induced by the systemic injection of pilocarpine, immediate seizure activity was increased, recurrent seizures following a one-time pilocarpine injection were facilitated, and this was thought to be due to the enhanced survival of hippocampal neural progenitor cells migrating into ectopic locations and generating a pathological pacemaker (Rozmer et al., 2017).

The production of the neurotoxic molecules, β-amyloid (Aβ), and hyperphosphorylated tau have been assumed to cause AD and the cardinal clinical symptom, cognitive deterioration (Illes, Burnstock, & Tang, 2019). A diversity of investigations with primary microglial cultures and in vivo AD animal models suggested that Aβ induces an increase in [Ca2+]i, in microglia via P2X7 receptor stimulation and the subsequent massive release of ATP (Sanz et al., 2009). A possible chain of events is that ATP released from damaged CNS cell types stimulates microglial P2X7 receptors and releases IL-1β, as well as other cell products. The beneficial effects of BBB-permeable P2X7 receptor antagonists in AD animal models also support the notion of pathological microglial activation in AD (Csöllő et al., 2013).

As already mentioned, the SNP Gln460Arg-P2X7 receptor is thought to be a predisposing factor for the affective diseases, major depression and bipolar disease. In addition, various models of inescapable rodent stress lead to the generation of a behavioural reaction termed "learned helplessness" (Illes, Rubini, Huang, & Tang, 2019). This is believed to be due to the increased secretion of adrenocorticotropic hormone (ACTH), and subsequently glucocorticoids, thought to cause depressive-like behaviour. Re-stimulation of microglial toll-like receptors (TLRs) and P2X7 receptors by DAMPs (ATP itself is the most ubiquitous DAMP) triggers NLRP3 activation and the associated IL-1β release, which is probably a major stimulus for the corticotropin-releasing hormone-induced activation of the hypothalamic–pituitary–adrenal axis. In fact, P2X7 receptor KO mice by themselves and WT mice after the application of P2X7 receptor antagonists exhibited an anti-depressant-like profile in animal models of major depression and bipolar disorder (Basso et al., 2009).

13 | CONCLUSIONS

P2X receptors appear very early in phylogeny (algae, amoeba, and basal fungi), and it is a fascinating property of these primitive receptors that, in contrast to their mammalian counterparts, they are expressed predominantly or even exclusively intracellularly. The mammalian P2X1–7 receptors reside mainly in the plasma membrane, and their ATP-induced opening and the subsequent cationic fluxes can regulate many essential cellular functions. Our knowledge of P2X receptor structure/function has greatly increased in the four decades elapsing since their discovery. Crystallization of the truncated zfP2X4 receptor disclosed the structure of a chalice-shaped trimeric receptor that allows cations to flow through fenestrations to the vestibules near the ion channel, resulting in TM ion fluxes. The zfP2X4 receptor served as a pattern for homology modelling of mammalian P2X receptor subtypes before they were crystallized and their 3D structure resolved.

Medical chemistry has made major contributions to the field by synthesizing subtype-selective antagonists and, with some temporal delay, PAMs and NAMs. This is a prerequisite of any conclusive experimental work and was therefore essential for moving the field ahead. Some of these antagonists were already prospective drugs in that they had favourable bioavailability after oral application and in case of an intended CNS activity, acutely crossed the BBB. Indispensable for research activities was the generation of a battery of transgenic animals. Reporter mice that express soluble fluorescent reporter proteins or fluorescent protein-tagged P2X receptors allowed targeted investigations of receptor-containing cells or their subcellular compartments.

Especially important was the assignment of deficiencies in individual P2X receptor subtypes to certain diseases with a genetic background and more recently population genetic studies aimed at the identification of loss-of-function SNPs pathogenically involved, for example, in affective diseases. In conclusion, structural deficiencies of P2X receptors may underlie certain illnesses, and on the contrary, selective antagonists or NAMs may correct the deleterious consequences of a pathological overstimulation by ATP (e.g., neuropathic/ inflammatory pain or neurodegenerative illnesses). Although a P2X...
receptor-based, widely used, drug is still missing in our therapeutic repertoire, the pharmaceutical industry is working intensively in this field and there is strong hope of achieving a major breakthrough in the near future (Cully, 2020; Krajewski, 2020).

13.1 Nomenclature of targets and ligands

Key protein targets and ligands in this article are hyperlinked to corresponding entries in the IUPHAR/BPS Guide to PHARMACOLOGY (https://www.guidetopharmacology.org) and are permanently archived in the Concise Guide to PHARMACOLOGY 2019/20 (Alexander, Christopoulos et al., 2019; Alexander, Fabbro et al., 2019; Alexander, Mathie et al., 2019).

ACKNOWLEDGEMENTS

P.I. was supported by the Chengdu University of Traditional Chinese Medicine in order to build up the International Collaborative Center on Big Science Plan for Purinergic Signaling (CZYHW1901) and a grant of the State Administration of Foreign Experts Affairs to support his stay in Chengdu (G20190236012). Work in A.N.’s laboratory was supported by the European Union’s Horizon 2020 Framework Programme research and innovation programme under the Marie Skłodowska-Curie grant agreement (766124) and the Deutsche Forschungsgemeinschaft (Project ID 335447717 – SFB 1328). F.D.V. was supported by the Italian Association for Cancer Research (Associazione Italiana per la Ricerca sul Cancro [AIRC]) Grants IG 13025, IG 18581, and IG 22883 and the Ministry of University and Research of Italy, PRIN 2017 Grant 8YTNWC, and funds from the University of Ferrara (Università degli Studi di Ferrara). Open access funding enabled and organized by Projekt DEAL.

CONFLICT OF INTEREST

F.D.V. is a member of the Scientific Advisory Board of Biosceptre Ltd, a UK-based biotech company involved in the development of P2X7-targeted therapeutic antibodies. The other authors declare no competing interest.

DATA AVAILABILITY STATEMENT

Data sharing is not applicable in this article because no new data were created or analysed in this study.

ORCID

Peter Illes https://orcid.org/0000-0003-0484-9389
Christa E. Müller https://orcid.org/0000-0002-0013-6624
Charles Kennedy https://orcid.org/0000-0001-9661-5437
Francesco Di Virgilio https://orcid.org/0000-0003-3566-1362

REFERENCES

Abbracchio, M. P., Burnstock, G., Boeynaems, J. M., Barnard, E. A., Boyer, J. L., Kennedy, C., … Weisman, G. A. (2006). International Union of Pharmacology LVIII: Update on the P2Y G protein-coupled nucleotide receptors: From molecular mechanisms and pathophysiology to therapy. Pharmacological Reviews, 58, 281–341. https://doi.org/10.1124/pr.58.3.3
Abdelrahman, A., Namisivayam, V., Hinz, S., Schiedel, A. C., Köse, M., Burton, M., … Müller, C. E. (2017). Characterization of P2X4 receptor agonists and antagonists by calcium influx and radioligand binding studies. Biochemical Pharmacology, 125, 41–54. https://doi.org/10.1016/j.bcp.2016.11.016
Adinolfi, E., Raffaghello, L., Giuliani, A. L., Cavazzini, L., Capece, M., Chiozzi, P., … Di Virgilio, F. (2012). Expression of P2X7 receptor increases in vivo tumor growth. Cancer Research, 72, 2957–2969. https://doi.org/10.1158/0008-5472.CAN-11-1947
Alexander, S. P. H., Christopoulos, A., Davenport, A. P., Kelly, E., Mathie, A., Peters, J. A., … CGTP Collaborators. (2019). THE CONCISE GUIDE TO PHARMACOLOGY 2019/20: G protein-coupled receptors. British Journal of Pharmacology, 176, S21–S141. https://doi.org/10.1111/bph.14748
Alexander, S. P. H., Fabbro, D., Kelly, E., Mathie, A., Peters, J. A., Veale, E. L., … CGTP Collaborators. (2019). THE CONCISE GUIDE TO PHARMACOLOGY 2019/20: Catalytic receptors. British Journal of Pharmacology, 176, S247–S526. https://doi.org/10.1111/bph.14751
Alexander, S. P. H., Mathie, A., Peters, J. A., Veale, E. L., Striessnig, J., Kelly, E., … Davies, J. A. (2019). The Concise Guide to PHARMACOLOGY 2019/20: Ion channels. British Journal of Pharmacology, 176(Suppl 1), S514–S522.
Aschrafi, A., Sadtler, S., Niculescu, C., Rettinger, J., & Schmalzing, G. (2004). Trimeric architecture of homomeric P2X2 and heteromeric P2X1,2 receptor subtypes. Journal of Molecular Biology, 342, 333–343. https://doi.org/10.1016/j.jmb.2004.06.092
Ase, A. R., Honson, N. S., Zaghdane, H., Pfeifer, T. A., & Seguela, P. (2015). Identification and characterization of a selective allosteric antagonist of human P2X4 receptor channels. Molecular Pharmacology, 87, 606–616. https://doi.org/10.1124/mol.114.096222
Baines, A., Parkinsson, K., Sim, J. A., Bragg, L., Thompson, C. R., & North, R. A. (2013). Functional properties of five Dicytostelium discoideum P2X receptors. The Journal of Biological Chemistry, 288, 20992–21000. https://doi.org/10.1074/jbc.M112.445346
Baqi, Y., Hausmann, R., Rosefort, C., Rettinger, J., Schmalzing, G., & Müller, C. E. (2011). Discovery of potent competitive antagonists and positive modulators of the P2X2 receptor. Journal of Medicinal Chemistry, 54, 817–830. https://doi.org/10.1021/jm1012193
Baroni, M., Pizzirani, C., Pinotti, M., Ferrari, D., Adinolfi, E., Calzavarini, S., … Di Virgilio, F. (2007). Stimulation of P2 (P2X)-receptor in human dendritic cells induces the release of tissue factor-bearing microparticles. The FASEB Journal, 21, 1926–1933. https://doi.org/10.1096/fj.06-7238com
Bartlett, R., Stokes, L., & Sylver, R. (2014). The P2X7 receptor channel: Recent developments and the use of P2X7 antagonists in models of disease. Pharmacological Reviews, 66, 638–675. https://doi.org/10.1124/pr.113.080003
Basso, A. M., Bratcher, N. A., Harris, R. R., Jarvis, M. F., Decker, M. W., & Rueter, L. E. (2009). Behavioral profile of P2X3 receptor knockout mice in animal models of depression and anxiety: Relevance for neuropsychiatric disorders. Behavioural Brain Research, 198, 83–90. https://doi.org/10.1016/j.bbr.2008.10.018
Bernier, L. P., Ase, A. R., Chevallier, S., Blais, D., Zhao, Q., Boue-Grabot, E., … Seguela, P. (2008). Phosphoinositides regulate P2X4 ATP-gated channels through direct interactions. The Journal of Neuroscience, 28, 12938–12945. https://doi.org/10.1523/JNEUROSCI.3038-08.2008
Bernier, L. P., Ase, A. R., & Seguela, P. (2018). P2X7 receptor channels in chronic pain pathways. British Journal of Pharmacology, 175, 2219–2230. https://doi.org/10.1111/bph.13957
Bertin, E., Deluc, T., Pilch, K. S., Martínez, A., Poujnet, J. T., Doudnikoff, E., … Boue-Grabot, E. (2020). Increased surface P2X4 receptor regulates
anxiety and memory in P2X4 internalization-defective knock-in mice. *Molecular Psychiatry*, 86, 1–16.

Bjelobaba, I., Janjic, M. M., & Stojilkovic, S. S. (2015). Purinergic signaling pathways in endocrine system. *Autonomic Neuroscience*, 191, 102–116. https://doi.org/10.1016/j.autneu.2015.04.010

Bo, X., Jiang, L. H., Wilson, H. L., Kim, M., Burnstock, G., Surprenant, A., & North, R. A. (2003). Pharmacological and biophysical properties of the human P2X7 receptor. *Molecular Pharmacology*, 63, 1407–1416. https://doi.org/10.1124/mol.63.6.1407

Bobanovic, L. K., Royle, J. S., & Murrell-Lagardno, R. D. (2002). P2X receptor trafficking in neurons is subunit specific. *The Journal of Neuroscience*, 22, 4814–4824.

Borges da Silva, H., Beura, L. K., Wang, H., Hanse, E. A., Gore, R., Scott, M. C., ... Jiang, L. H., Wilson, H. L., Kim, M., Burnstock, G., & Burnstock, G., & Sivilotti, L., Colquhoun, D., Burnstock, G., & Surprenant, A., & Chen, C. C., Akopian, A. N., Sivilotti, L., Colquhoun, D., Burnstock, G., & Wood, J. N. (1995). A P2X purinoceptor expressed by a subset of sensory neurons. *Nature*, 377, 428–431. https://doi.org/10.1038/377428a0

Cockayne, D. A., Dunn, P. M., Zhang, Y., Rong, W., Hamilton, S. G., Knight, G. E., ... Ford, A. P. (2005). P2X7 knockout mice and P2X7/P2X6 double knockout mice reveal a role for the P2X7 receptor subunit in mediating multiple sensory effects of ATP. *The Journal of Physiology*, 567, 621–639. https://doi.org/10.1113/jphysiol.2005.088435

Coddou, C., Stojilkovic, S. S., & Huidobro-Toro, J. P. (2011). Allosteric modulation of ATP-gated P2X receptor channels. *Reviews in the Neurosciences*, 22, 335–354. https://doi.org/10.1515/RNS.2011.014

Collo, G., North, R. A., Kawashima, E., Merlo-Pich, E., Neidhart, S., Surprenant, A., & Buell, G. (1996). Cloning of P2X5 and P2X6 receptors and the distribution and properties of an extended family of ATP-gated ion channels. *The Journal of Neuroscience*, 16, 2495–2507

Csölle, C., Anda, R. D., Kittel, A., Gölöncser, F., Baranyi, M., Soproni, K., ... Sperliagh, B. (2013). The absence of P2X7 receptors (P2X7) on non-haematopoietic cells leads to selective alteration in mood-related behaviour with dysregulated gene expression and stress reactivity in mice. *The International Journal of Neuropsychopharmacology*, 16, 213–233. https://doi.org/10.1017/S1461145711001933

Cully, M. (2020). Can anti-inflammatory strategies light up the dim depression pipeline? *Nature Reviews. Drug Discovery*, 19, 224–225. https://doi.org/10.1038/s41457-020-00049-5

Dal Ben, D., Buccioni, M., Lambertiucchi, C., Marucci, G., Spinaci, A., Marchenкова, A., ... Volpini, R. (2019). Investigation on 2',3'-O-substituted ATP derivatives and analogs as novel P2X3 receptor antagonists. *ACS Medicinal Chemistry Letters*, 10, 493–498. https://doi.org/10.1021/acsmedchemlett.9b00524

Dhuna, K., Felgate, M., Bidula, S. M., Walpole, S., Bibic, L., Cromer, B. A., ... Stokes, L. (2019). Ginsenosides act as positive modulators of P2X4 receptors. *Molecular Pharmacology*, 95, 210–221. https://doi.org/10.1124/mol.118.113696

Di Virgilio, F., Dal Ben, D., Sarti, A. C., Giuliani, A. L., & Falzoni, S. (2017). The P2X7 receptor in infection and inflammation. *Immunity*, 47, 15–31. https://doi.org/10.1016/j.immuni.2017.06.020

Di Virgilio, F., Sarti, A. C., & Coutinho-Silva, R. (2020). Purinergic signaling, DAMPs, and inflammation. *American Journal of Physiology. Cell Physiology*, 318, C832–C835. https://doi.org/10.1152/ajpcell.00053.2020

Di Virgilio, F., Sarti, A. C., Falzoni, S., De Marchi, E., & Adinolfi, E. (2018). Extracellular ATP and P2 purinergic signalling in the tumour microenvironment. *Nature Reviews. Cancer*, 18, 601–618. https://doi.org/10.1038/s41580-018-0037-0

Donnelly-Roberts, D. L., Namovic, M. T., Han, P., & Jarvis, M. F. (2009). Mammalian P2X7 receptor pharmacology: Comparison of recombimant mouse, rat and human P2X7 receptors. *British Journal of Pharmacology*, 157, 1203–1214. https://doi.org/10.1111/j.1476-5381.2009.02233.x

Duckwitz, W., Hausmann, R., Aschrafi, A., & Schmalzing, G. (2006). ATPergic signal activation through the stimulation of P2X1 receptors. *Neuropharmacology*, 51, 1–10. https://doi.org/10.1016/j.neuropharm.2015.11.001

Engel, T., Alves, M., Sheedy, C., & Henshall, D. C. (2016). ATPergic signalling: From normal behaviour to pathological brain function. *Progress in Neurobiology*, 95, 229–274. https://doi.org/10.1016/j.pneurobio.2011.08.006

Finger, T. E., Danilova, V., Barrows, J., Bartel, D. L., Vigers, A. J., Stone, L., ... Kinnamon, S. C. (2018). The purinergic receptor P2RX7 passenger mutation affects the vitality and differentiation of Th17 cells and type II collagen-induced arthritis in mice. *Molecular Psychiatry*, 23, 907–918. https://doi.org/10.1038/s41380-017-0077-z

Finger, T. E., Dal Ben, D., Buccioni, M., Lambertiucchi, C., Marucci, G., Spinaci, A., Marchenкова, A., ... Volpini, R. (2019). Investigation on 2',3'-O-substituted ATP derivatives and analogs as novel P2X3 receptor antagonists. *ACS Medicinal Chemistry Letters*, 10, 493–498. https://doi.org/10.1021/acsmedchemlett.9b00524

Finger, T. E., Danilova, V., Barrows, J., Bartel, D. L., Vigers, A. J., Stone, L., ... Kinnamon, S. C. (2005). ATP signaling is crucial for communication from taste buds to gustatory nerves. *Science*, 310, 1495–1499. https://doi.org/10.1126/science.1118435
Ford, A. P. (2012). In pursuit of P2X3 antagonists: Novel therapeutics for chronic pain andafferent sensitization. Purinergic Signal, 8, 3–26. https://doi.org/10.1007/s11302-011-9271-6

Ford, A. P., & Undem, B. J. (2013). The therapeutic promise of ATP antagonism at P2X3 receptors in respiratory and urological disorders. Frontiers in Cellular Neuroscience, 7, 267.

Fountain, S. J. (2013). Primitive ATP-activated P2X receptors: Discovery, function and pharmacology. Frontiers in Cellular Neuroscience, 7, 247.

Fountain, S. J., & Burnstock, G. (2009). An evolutionary history of P2X receptors. Purinergic Signal, 5, 269–272. https://doi.org/10.1007/s11302-006-9127-x

Fountain, S. J., Parkinson, K., Young, M. T., Cao, L., Thompson, C. R., & North, R. A. (2007). An intracellular P2X receptor required for osmoregulation in Dictyostelium discoideum. Nature, 448, 200–203. https://doi.org/10.1038/nature05926

Garceau, D., & Chauret, N. (2019). BLU-5937: A selective P2X3 antagonist with potent anti-tussive effect and no taste alteration. Pulmonary Pharmacology & Therapeutics, 56, 56–62. https://doi.org/10.1016/j.pupt.2019.03.007

Gelin, C. F., Bhattacharya, A., & Letavic, M. A. (2020). P2X7 receptor antagonists for the treatment of systemic inflammatory disorders. Progress in Medicinal Chemistry, 59, 63–99. https://doi.org/10.1016/bspmch.2019.11.002

George, B., Swartz, K. J., & Li, M. (2019). Hearing loss mutations alter the functional properties of human P2X2 receptor channels through distinct mechanisms. Proceedings of the National Academy of Sciences of the United States of America, 116, 22862–22871. https://doi.org/10.1073/pnas.1912156116

Gong, D., Zhang, J., Chen, Y., Mi, Q. B., Yao, X. J., Smith, E., Barry, W. H., & Liang, B. T. (2001). A novel contractile phenotype with cardiac transgenic expression of the human P2X1 receptor. The FASEB Journal, 15, 2739–2741. https://doi.org/10.1096/fj.01-04459fj

Huang, Y. A., Stone, L. M., Pereira, E., Yang, R., Kinnamon, J. C., Dvoryanchikov, G., ... Roper, S. D. (2011). Knocking out P2X2 receptors reduces transmitter secretion in taste buds. The Journal of Neuroscience, 31, 13654–13661. https://doi.org/10.1523/JNEUROSCI.3356-11.2011

Illes, P., Burnstock, G., & Tang, Y. (2019). Astroglia-derived ATP modulates CNS neuronal circuits. Trends in Neurosciences, 42, 885–898. https://doi.org/10.1016/j.tins.2019.09.006

Illes, P., Khan, T. M., & Rubini, P. (2017). Neuronal P2X7 receptors revisited: Do they really exist? The Journal of Neuroscience, 37, 7049–7062. https://doi.org/10.1523/JNEUROSCI.3103-16.2017

Illes, P., Rubini, P., Huang, L., & Tang, Y. (2019). The P2X7 receptor: A new therapeutic target in Alzheimer’s disease. Expert Opinion on Therapeutic Targets, 23, 165–176. https://doi.org/10.1080/14728222.2019.1575811

Illes, P., Verkhratsky, A., & Tang, Y. (2019). Pathological ATPergic signaling in major depression and bipolar disorder. Frontiers in Molecular Neuroscience, 12, 331.

Ilyaskin, A. V., Sure, F., Nesterov, V., Haertsie, S., & Korbmacher, C. (2019). Bile acids inhibit human purinergic receptor P2X4 in a heterologous expression system. The Journal of General Physiology, 151, 820–833. https://doi.org/10.1085/jgp.201812291

Inoue, K. (2019). Role of the P2X4 receptor in neuropathic pain. Current Opinion in Pharmacology, 47, 33–39. https://doi.org/10.1016/j.coph.2019.02.001

Jacobson, K. A., Delicado, E. G., Gachet, C., Kennedy, C., von Kügelgen, I., Li, B., ... Müller, C. E. (2020). Update of P2Y receptor pharmacology: IUPHAR Review 27. British Journal of Pharmacology, 177, 2413–2433. https://doi.org/10.1111/bph.15005

Jacobson, K. A., Kim, Y. C., Wildman, S. S., Mohanram, A., Harden, T. K., Boyer, J. L., ... Burnstock, G. (1998). A pyridine cyclic phosphate and its 6-azoaryl derivative selectively potentiate and antagonize activation of P2X3 receptors. Journal of Medicinal Chemistry, 41, 2201–2206. https://doi.org/10.1021/jm980183o

Jacobson, K. A., & Müller, C. E. (2016). Medicinal chemistry of adenosine, P2Y and P2X receptors. Neuropharmacology, 104, 31–49. https://doi.org/10.1016/j.neuropharm.2015.12.001

Janks, L., Sprague, R. S., & Egan, T. M. (2019). ATP-gated P2X7 receptors require chloride channels to promote inflammation in human macrophages. Journal of Immunology, 202, 883–898. https://doi.org/10.4049/jimmunol.1801101

Jarvis, M. F., Khakh, B. S. (2009). ATP-gated P2X receptors. The FASEB Journal, 23, 8903–8910. https://doi.org/10.1096/fj.09-155739

Jimenez-Mateos, E. M., Smith, J., Nicke, A., & Engel, T. (2019). Regulation of P2X7 receptor expression and function in the brain. Brain Research Bulletin, 151, 153–163.

Jones, C. A., Vial, C., Sellers, L. A., Humphrey, P. P., Evans, R. J., & Chessell, I. P. (2004). Functional regulation of P2X2 receptors by N-linked glycosylation: Identification of a novel α1-methylene ATP-sensitive pathway. Molecular Pharmacology, 65, 979–985. https://doi.org/10.1124/mol.65.4.979

Kaczmarek-Hajek, K., Lörinczi, E., Hausmann, R., & Nicke, A. (2012). Molecular and functional properties of P2X receptors—Recent progress and persisting challenges. Purinergic Signal, 8, 375–417. https://doi.org/10.1007/s11302-012-9314-7

Kaczmarek-Hajek, K., Zhang, J., Koop, R., Grosche, A., Rissiek, B., Saul, A., ... Nicke, A. (2018). Re-evaluation of neuronal P2X7 expression using...
novel mouse models and a P2X7-specific nanobody. eLife, 7, e36217. https://doi.org/10.7554/eLife.36217
Karasia, A., & Kawate, T. (2016). Structural basis for subtype-specific inhibition of the P2X7 receptor. eLife, 5, e22153. https://doi.org/10.7554/eLife.22153
Karasia, A., Michalski, K., Mikhelzon, P., & Kawate, T. (2017). The P2X7 receptor forms a dye-permeable pore independent of its intracellular domain but dependent on membrane lipid composition. eLife, 6, e31186. https://doi.org/10.7554/eLife.31186
Karmakar, M., Katsnelson, M. A., Dubyak, G. R., & Pearlman, E. (2016). Neutrophil P2X7 receptors mediate NLRP3 inflammasome-dependent IL-1β secretion in response to ATP. Nature Communications, 7, 10555. https://doi.org/10.1038/ncomms10555
Kasuya, G., Fujiwara, Y., Takemoto, M., Dohmae, N., Nakada-Nakura, Y., Ishitani, R., ... Nureki, O. (2016). Structural insights into divergent cation modulations of ATP-gated P2X receptor channels. Cell Reports, 14, 932–944. https://doi.org/10.1016/j.celrep.2015.12.087
Kasuya, G., Fujiwara, Y., Tsukamoto, H., Morinaga, S., Ryu, S., Touhara, K., ... Nureki, O. (2017). Structural insights into the nucleotide base specificity of P2X receptors. Scientific Reports, 7, 45208. https://doi.org/10.1038/srep45208
Khakh, B. S., & North, R. A. (2012). Neuromodulation by extracellular ATP and P2X receptors and their subunits. Autonomic Neuroscience, XXIV. Current status of the nomenclature and properties of P2X receptors and their subunits. Pharmacological Reviews, 53, 107–118.
Khakh, B. S., & North, R. A. (2012). Neuroumodulation by extracellular ATP and P2X receptors in the CNS. Neuron, 76, 51–69. https://doi.org/10.1016/j.neuron.2012.09.024
Khakh, B. S., Proctor, W. R., Dunwiddie, T. V., Labarca, C., & Lester, H. A. (1999). AllostERIC control of gating and kinetics at P2X2 receptor channels. The Journal of Neuroscience, 19, 7289–7299. https://doi.org/10.1523/JNEUROSCI.19-17-07289.1999
Kim, H., Kajikawa, T., Walsh, M. C., Takeghara, N., Jeong, Y. H., Hajishengallis, G., & Choi, Y. (2018). The purinergic receptor P2X5 contributes to bone loss in experimental periodontitis. BMB Reports, 51, 468–473.
Kim, H., Walsh, M. C., Takeghara, N., Middleton, S. A., Shin, H. I., Kim, J., & Choi, Y. (2017). The purinergic receptor P2X5 regulates inflammasome activity and hypermultinculation of murine osteoclasts. Scientific Reports, 7, 196. https://doi.org/10.1038/s41598-017-00139-2
Kim, S. H., Bahia, P. K., Patil, M., Sutton, S., Sowell, I., Hadley, S. H., ... Taylor-Clark, T. E. (2020). Development of a mouse reporter strain for the purinergic P2X2 receptor. eNeuro, 7, 203–220.
Kotnis, S., Bingham, B., Vasiliev, D. V., Miller, S. W., Bai, Y., Yeola, S., ... Whiteside, G. T. (2010). Genetic and functional analysis of human P2X5 reveals a distinct pattern of exon 10 polymorphism with predominant expression of the nonfunctional receptor isoform. Molecular Pharmacology, 77, 953–960. https://doi.org/10.1124/mol.110.063636
Kowalski, M., Hausmann, R., Schmid, J., Dopychau, A., Stephan, G., Tang, Y., ... Rubini, P. (2015). Flexible subunit stoichiometry of functional human P2X2/3 heteromeric receptors. Neuropharmacology, 99, 115–130. https://doi.org/10.1016/j.neuropharm.2015.07.008
Krajewski, J. L. (2020). P2X3-containing receptors as targets for the treatment of chronic pain. Neurotherapeutics, 1–13. https://doi.org/10.1007/s13311-020-00934-2
Lambertucci, C., Dal Ben, D., Bucconi, M., Marucci, G., Thomas, A., & Volpini, P. (2015). Medicinal chemistry of P2X2 receptors: Agonists and orthosteric antagonists. Current Medicinal Chemistry, 22, 915–928. https://doi.org/10.2174/0929867321664141215093513
Le, K. T., Paquet, M., Noulé, D., Babin, R., & Seguela, P. (1997). Primary structure and expression of a naturally truncated human P2X ATP receptor subunit from brain and immune system. FEBS Letters, 418, 149–199. https://doi.org/10.1016/S0014-5793(97)01380-X
Lecut, C., Facchinetti, C., Delerueux, C., van, O. R., Sprok, H. M., Evans, R. J., ... Oury, C. (2012). ATP-gated P2X, ion channels protect against endotoxemia by dampening neutrophil activation. Journal of Thrombosis and Haemostasis, 10, 453–465. https://doi.org/10.1111/j.1538-7836.2011.04606.x
Lewis, C., Neidhart, S., Holy, C., North, R. A., Buell, G., & Surprenant, A. (1995). Coexpression of P2X2 and P2X3 receptor subunits can account for ATP-gated currents in sensory neurons. Nature, 377, 432–435. https://doi.org/10.1038/377432a0
Li, M., Silberberg, S. D., & Swartz, K. J. (2013). Subtype-specific control of P2X receptor channel signaling by ATP and Mg2+. Proceedings of the National Academy of Sciences of the United States of America, 110, E3455–E3463. https://doi.org/10.1073/pnas.1308088110
Mahaut Smith, M. P., Evans, R. J., & Vial, C. (2019). Development of a P2X1-eIFP receptor knock-in mouse to track receptors in real time. Purinergic Signal, 15, 397–402. https://doi.org/10.1007/s11302-019-09666-1
Maitre, B., Magenstret, S., Heim, V., Ravanat, C., Evans, R. J., de la Salle, H., ... Hechler, B. (2015). The P2X1 receptor is required for neutrophil extravasation during lipopolysaccharide-induced lethal endotoxemia in mice. Journal of Immunology, 194, 739–749. https://doi.org/10.4049/jimmunol.1401786
Mansoor, S. E., Liu, W., Oosterheert, W., Shekhar, M., Tajkhorshid, E., & Gouaux, E. (2016). X-ray structures define human P2X3 receptor gating cycle and antagonist action. Nature, 538, 66–71. https://doi.org/10.1038/nature19267
Marucci, G., Dal Ben, D., Bucconi, M., Marti, N. A., Spinaci, A., Volpini, R., & Lambertucci, C. (2019). Update on novel purinergic P2X3 and P2X2/3 receptor antagonists and their potential therapeutic applications. Expert Opinion on Therapeutic Patents, 29, 943–963. https://doi.org/10.1080/13543776.2019.1693542
Matsumura, Y., Yamashita, T., Sasaki, A., Nakata, E., Kohno, K., Masuda, T., ... Inoue, K. (2016). A novel P2X4 receptor-selective antagonist produces anti-aldolycic effect in a mouse model of herpetic pain. Scientific Reports, 6, 32461. https://doi.org/10.1038/srep32461
McCarthy, A. E., Yoshioka, C., & Mansoor, S. E. (2019). Full-length P2X4 structures reveal how palmitoylation prevents channel desensitization. Cell, 179, 659–670. https://doi.org/10.1016/j.cell.2019.09.017
Mittal, R., Chan, B., Grati, M., Mittal, J., Patel, K., Debs, L. H., ... Volpini, R. (2015). Medicinal chemistry of P2X3 receptors: Agonists and orthosteric antagonists. Expert Opinion on Therapeutic Patents, 29, 943–963. https://doi.org/10.1080/13543776.2019.1693542
Montilla, A., Mata, G. P., Matute, C., & Domerçç, M. (2020). Contribution of P2X4 receptors to CNS function and pathophysiology. International Journal of Molecular Sciences, 21, 5562. https://doi.org/10.3390/ijms21155562
Moric, A. H., Kitt, M. M., Ford, A. P., Tershakovec, A. M., Wu, Brindle, K., ... Müller, C. E. (2010). Emerging structures and ligands for P2X3 and P2X4 receptors—Towards novel treatments of neuropathic pain. Purinergic Signaling, 6, 145–148. https://doi.org/10.1007/s11302-010-9182-y

Müller, C. E. (2015). Medicinal chemistry of P2X receptors: Allosteric modulators. Current Medicinal Chemistry, 22, 929–941. https://doi.org/10.2174/0929867322666141210155610

Müller, C. E. (2010). The cytolytic P2Z receptor for extracellular ATP identified as a P2X receptor. The Journal of Biological Chemistry, 273, 15177–15182. https://doi.org/10.1074/jbc.M006781200

Nicken, A., Müller, R., Gasser, C., Plattner, P., Palm, R., ... Müller, C. E. (2020). Discovery and structure relationships of P2X2 receptor antagonists for the treatment of refractory or unexplained chronic cough: A randomised, double-blind, controlled, parallel-group, phase 2b trial. The Lancet Respiratory Medicine, 8, 775–785. https://doi.org/10.1016/S2213-2600(19)30471-0

North, T. M. (2013). P2X4 receptor is associated with increased pulse pressure. Journal of Physiology, 591.176180. https://doi.org/10.1113/jphysiol.2012.256621

North, R. A. (2002). Molecular physiology of P2X receptors. Physiological Reviews, 82, 1013–1067. https://doi.org/10.1152/physrev.00015.2002

North, R. A., & Jarvis, M. F. (2013). P2X receptors as drug targets. Current Medicinal Chemistry, 20, 15177–15182. https://doi.org/10.2174/0929867321666141210155610

Illes, P. (2017). Pilocarpine-induced status epilepticus increases the sensitivity of P2X7 and P2Y1 receptors to nucleotides at neural progenitor cells of the juvenile rodent hippocampus. Cerebral Cortex, 27, 3568–3585. https://doi.org/10.1093/cercor/bhw178

Skarnes, W. C., Rosen, B., West, A. P., Koutsourakis, M., Bushell, W., Iyer, V., ... Bradley, A. (2011). A conditional knockout resource for the genome-wide study of mouse gene function. Nature, 474, 337–342. https://doi.org/10.1038/nature10163

Slyuter, R. (2017). The P2X7 receptor. Advances in Experimental Medicine and Biology, 1051, 17–53Ref ID: 145. https://doi.org/10.1007/5584_2017_59

Smith, J. A., Kitt, M. M., Morice, A. H., Birring, S. S., McGarvey, L. P., Sher, M. R., ... Ford, A. P. (2020). Gefapixant, a P2X3 receptor antagonist, for the treatment of refractory or unexplained chronic cough: A randomised, double-blind, controlled, parallel-group, phase 2b trial. The Lancet Respiratory Medicine, 8, 775–785. https://doi.org/10.1016/S2213-2600(19)30471-0

Svolos, L., Labasi, J., Perrepaux, D. G. S. O., Stam, E., Petrushova, N., Koller, B. H., ... Gavel, C. A. (2001). Altered cytokine production in mice lacking P2X7 receptors. The Journal of Biological Chemistry, 276, 125–132. https://doi.org/10.1074/jbc.M006781200

Stokes, L., Scurrath, K., Ellis, J. A., Cromer, B. A., Skarratt, K. K., Gu, B. J., ... Wiley, J. S. (2011). A loss-of-function polymorphism in the human P2X4 receptor is associated with increased pulse pressure. Hypertension, 58, 1086–1092. https://doi.org/10.1161/HYPERTENSIONAHA.111.176180

Sun, L. F., Liu, Y., Wang, J., Huang, L. D., Yang, Y., Cheng, X. Y., ... Yu, Y. (2019). Altered allostery of the left flipper domain underlies the weak ATP response of rat P2X5 receptors. The Journal of Biological Chemistry, 294, 19589–19603. https://doi.org/10.1074/jbc.RA119.009959

Surprenant, A., Rassendren, F., Kawashima, E., North, R. A., & Buell, G. (1996). The cytolitic P2Z receptor for extracellular ATP identified as a novel P2X receptor (P2X5). Science, 272, 735–738. https://doi.org/10.1126/science.272.5262.735

Teixeira, J. M., Dos Santos, G. G., Neves, A. F., Athie, M. C. P., Bonet, I. J. M., Nishijima, C. M., ... Parada, C. A. (2019). Diabetes-induced neuropathic mechanical hyperalgesia depends on P2X4 receptor activation in dorsal root ganglia. Neuroscience, 398, 158–170. https://doi.org/10.1016/j.neuroscience.2018.12.003

Tian, M., Abdelrahman, A., Baqi, Y., Fuentes, E., Azazna, D., Spanier, C., ... Müller, C. E. (2020). Discovery and structure relationships of
salicylanilide derivatives as potent, non-acidic P2X1 receptor antagonists. *Journal of Medicinal Chemistry*, 63, 6164–6178. https://doi.org/10.1021/acs.jmedchem.0c00435

Valenzuela, D. M., Murphy, A. J., Frendewey, D., Gale, N. W., Economides, A. N., Auerbach, W., ... Yancopoulos, G. D. (2003). High-throughput engineering of the mouse genome coupled with high-resolution expression analysis. *Nature Biotechnology*, 21, 652–659. https://doi.org/10.1038/nbt822

Verkhratsky, A., Zimmermann, H., Abbracchio, M. P., Illes, P., & Di Virgilio, F. (2020). In memoriam Geoffrey Burnstock: Creator of purinergic signalling. *Function*, 1, zqaa006. https://doi.org/10.1093/function/zqaa006

Wang, Wang, Y., Cui, W. W., Huang, Y., Yang, Y., Liu, Y., ... Yu, Y. (2018). Druggable negative allosteric site of P2X3 receptors. *Proceedings of the National Academy of Sciences of the United States of America*, 115, 4939–4944. https://doi.org/10.1073/pnas.1809071115

Wera, O., Lecut, C., Servais, L., Hego, A., Delierneux, C., Jiang, Z., ... Oury, C. (2020). P2X1 ion channel deficiency causes massive bleeding in inflamed intestine and increases thrombosis. *Journal of Thrombosis and Haemostasis*, 18, 44–56. https://doi.org/10.1111/jth.14620

Werner, S., Mesch, S., Hillig, R. C., Ter, L. A., Klint, J., Neagoe, I., ... Steinmeyer, A. (2019). Discovery and characterization of the potent and selective P2X4 inhibitor N-[4-[(3-chlorophenoxy)-3-sulfamoylphényl]-2-phenylacetamido (BAY-1797) and structure-guided amelioration of its CYP3A4 induction profile. *Journal of Medicinal Chemistry*, 62, 11194–11217. https://doi.org/10.1021/acs.jmedchem.9b01304

Wolf, C., Rosefort, C., Fallah, G., Kassack, M. U., Hamacher, A., Bodnar, M., ... Hausmann, R. (2011). Molecular determinants of potent P2X2 antagonism identified by functional analysis, mutagenesis, and homology docking. *Molecular Pharmacology*, 79, 649–661. https://doi.org/10.1124/mol.110.068700

Xu, J., Bernstein, A. M., Wong, A., Lu, X. H., Khoja, S., Yang, X. W., ... Khakh, B. S. (2016). P2X4 receptor reporter mice: Sparse brain expression and feeding-related presynaptic facilitation in the arcuate nucleus. *The Journal of Neuroscience*, 36, 8902–8920. https://doi.org/10.1523/JNEUROSCI.1496-16.2016

Yan, D., Zhu, Y., Walsh, T., Xie, D., Yuan, H., Sirmaci, A., ... Liu, X. Z. (2013). Mutation of the ATP-gated P2X2 receptor leads to progressive hearing loss and increased susceptibility to noise. *Proceedings of the National Academy of Sciences of the United States of America*, 110, 2228–2233. https://doi.org/10.1073/pnas.1222285110

Yang, A., Sonin, D., Jones, L., Barry, W. H., & Liang, B. T. (2004). A beneficial role of cardiac P2X4 receptors in heart failure: Rescue of the calusequestrin overexpression model of cardiomyopathy, *American Journal of Physiology. Heart and Circulatory Physiology*, 287, H1096–H1103. https://doi.org/10.1152/ajpheart.00079.2004

Zemkova, H., Khadra, A., Rokic, M. B., Tvrdonova, V., Sherman, A., & Stojilkovic, S. S. (2015). Allosteric regulation of the P2X4 receptor channel pore dilation. *Pflügers Archiv*, 467, 713–726. https://doi.org/10.1007/s00424-014-1546-7

Zemkova, H., Tvrdonova, V., Bhattacharya, A., & Jindrichova, M. (2014). Allosteric modulation of ligand gated ion channels by ivermectin. *Physiological Research*, 63(Suppl. 1), S215–224.

---

**How to cite this article:** Illes P, Müller CE, Jacobson KA, et al. Update of P2X receptor properties and their pharmacology: IUPHAR Review 30. *Br J Pharmacol*. 2021;178:489–514. [https://doi.org/10.1111/bph.15299](https://doi.org/10.1111/bph.15299)